CANCER: Trials with potential global reach and other challenging trials
Lead Research Organisation:
University College London
Department Name: UNLISTED
Abstract
This program includes clinical trials that either present unusual challenges to design and conduct and/or have the potential for global impact (that is, studies of treatments that may more easily applied in even resource-poor countries).
Some of these trials test ‘repurposing’ an approved and marketed drug in an indication distinct from that for which it was licensed, thereby shortening the time needed to make a drug available to patients, and at lower cost.
Another area of focus has to do with the handful of cancer types in which there is a clear association to particular types of infections, such as hepatitis, helicobacter pylori, and human papilloma virus (HPV).
Finally, we use systematic reviews (compiling data from trials already completed anywhere) to identify areas of potential high-impact for new trials, for instance in relation to accuracy of prostate cancer diagnosis.
Some of these trials test ‘repurposing’ an approved and marketed drug in an indication distinct from that for which it was licensed, thereby shortening the time needed to make a drug available to patients, and at lower cost.
Another area of focus has to do with the handful of cancer types in which there is a clear association to particular types of infections, such as hepatitis, helicobacter pylori, and human papilloma virus (HPV).
Finally, we use systematic reviews (compiling data from trials already completed anywhere) to identify areas of potential high-impact for new trials, for instance in relation to accuracy of prostate cancer diagnosis.
Technical Summary
This theme relates to trials that either present unusual challenges to design and conduct and/or have the potential for global impact (that is, studies of specific relevance to both resource-poor and resource-rich countries). Challenging trials include those that draw upon this Unit’s specialised experience, such as those requiring extremely large recruitment numbers and/or practical experience managing international collaboration.
One class of trials with global reach involves tests of ‘repurposing’ an approved and marketed drug in an indication distinct from that for which it was licensed. There is currently considerable interest in re-evaluating commonly prescribed medications for their anti-cancer properties.
Repurposing studies have significant potential benefits. Demonstrating efficacy in a new clinical indication for drugs with known toxicity and pharmacokinetics bypasses or shortens some of the steps of the traditional drug evaluation pathway. It also provides access to drugs that are often relatively simple to administer and considerably less expensive than newer agents still within their patent life, and therefore of particular benefit in resource-limited settings. The assessment of aspirin as an adjuvant therapy in several different cancer types within the Add-Aspirin programme is a classic example of such repurposing, as is the ongoing PATCH trial which is evaluating oestradiol patches, designed originally for use in post-menopausal women, as a treatment for prostate cancer.
Systematic review is a key tool for deciding which agents are the best candidates for further evaluation; statins, vitamin D and metformin (an oral hypoglycaemic agent used to treat diabetes), amongst others, are currently being actively investigated for inclusion in either the STAMPEDE and/or the Add-Aspirin trial platforms.
In low resource countries, approximately one quarter of all cancers have been attributed to four chronic infectious causes: helicobacter pylori, hepatitis B and C, and human papilloma virus (HPV). HPV-associated tumours develop mainly in the ano-genital area and oropharynx and all have similar molecular signatures and clinical characteristics. We are actively exploring the feasibility of new platform trials that will bring together researchers with a common interest in HPV-related (or other infection-related) cancers. HPV cancers all contain foreign HPV antigens, which provides an opportunity to exploit immunological based therapies and strategies that have recently led to improved outcomes in other tumour types.
Some cancer trials fit into our portfolio because of particular challenges and their potential impact. Amongst these is the PROMIS study which is testing, in patients with suspected prostate cancer, a diagnostic pathway that includes Multi-Parametric Magnetic Resonance Imaging (MP-MRI). Whilst this is a UK-only study, it is in an extremely common disease setting and has the potential to reduce the substantial over-diagnosis and overtreatment of low grade prostate cancers that carry little risk to survival – a common problem across Western countries. Improving the diagnostic accuracy for prostate cancer, the most common neoplasm in men, would have a huge impact on resource usage, outcomes, and quality of life. Perhaps most importantly, it could provide the basis for a sound approach to prostate cancer screening which has thus far proved a challenge to public health authorities internationally.
One class of trials with global reach involves tests of ‘repurposing’ an approved and marketed drug in an indication distinct from that for which it was licensed. There is currently considerable interest in re-evaluating commonly prescribed medications for their anti-cancer properties.
Repurposing studies have significant potential benefits. Demonstrating efficacy in a new clinical indication for drugs with known toxicity and pharmacokinetics bypasses or shortens some of the steps of the traditional drug evaluation pathway. It also provides access to drugs that are often relatively simple to administer and considerably less expensive than newer agents still within their patent life, and therefore of particular benefit in resource-limited settings. The assessment of aspirin as an adjuvant therapy in several different cancer types within the Add-Aspirin programme is a classic example of such repurposing, as is the ongoing PATCH trial which is evaluating oestradiol patches, designed originally for use in post-menopausal women, as a treatment for prostate cancer.
Systematic review is a key tool for deciding which agents are the best candidates for further evaluation; statins, vitamin D and metformin (an oral hypoglycaemic agent used to treat diabetes), amongst others, are currently being actively investigated for inclusion in either the STAMPEDE and/or the Add-Aspirin trial platforms.
In low resource countries, approximately one quarter of all cancers have been attributed to four chronic infectious causes: helicobacter pylori, hepatitis B and C, and human papilloma virus (HPV). HPV-associated tumours develop mainly in the ano-genital area and oropharynx and all have similar molecular signatures and clinical characteristics. We are actively exploring the feasibility of new platform trials that will bring together researchers with a common interest in HPV-related (or other infection-related) cancers. HPV cancers all contain foreign HPV antigens, which provides an opportunity to exploit immunological based therapies and strategies that have recently led to improved outcomes in other tumour types.
Some cancer trials fit into our portfolio because of particular challenges and their potential impact. Amongst these is the PROMIS study which is testing, in patients with suspected prostate cancer, a diagnostic pathway that includes Multi-Parametric Magnetic Resonance Imaging (MP-MRI). Whilst this is a UK-only study, it is in an extremely common disease setting and has the potential to reduce the substantial over-diagnosis and overtreatment of low grade prostate cancers that carry little risk to survival – a common problem across Western countries. Improving the diagnostic accuracy for prostate cancer, the most common neoplasm in men, would have a huge impact on resource usage, outcomes, and quality of life. Perhaps most importantly, it could provide the basis for a sound approach to prostate cancer screening which has thus far proved a challenge to public health authorities internationally.
Organisations
- University College London (Lead Research Organisation)
- Danish Cancer Society (Collaboration)
- University of Colorado Boulder (Collaboration)
- Canadian Cancer Trials Group (Collaboration)
- European Organisation for Research and Treatment of Cancer (EORTC) (Collaboration)
- Uppsala University Hospital (Collaboration)
- Korean Gynaecological Oncology Group (Collaboration)
- Helsinki University Hospital (Collaboration)
- National Cancer Institute (NCI) (Collaboration)
- Wales Cancer Bank (Collaboration)
- Vanderbilt University (Collaboration)
- University College Hospital (Collaboration)
- British Columbia Cancer Agency (BCCA) (Collaboration)
- Hospital La Luz (Collaboration)
- Scandinavian Sarcoma Group (SSG) (Collaboration)
- FREEMAN HOSPITAL (Collaboration)
- Yokohama City University Medical Centre (Collaboration)
- The Christie Hospital (Collaboration)
- Sir Dorabji Tata Trust (Collaboration)
- PUBLIC HEALTH ENGLAND (Collaboration)
- Sapienza University of Rome (Collaboration)
- Circolo Hospital and Macchi Foundation (Collaboration)
- UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST (Collaboration)
- The University of Texas at San Antonio (Collaboration)
- UNIVERSITY OF CAMBRIDGE (Collaboration)
- MERCK (Collaboration)
- Cancer Research UK (Collaboration)
- Bayer (Collaboration)
- Australia and New Zealand Gynaecological Oncology Group (Collaboration)
- Queen Elizabeth Hospital Birmingham (Collaboration)
- Tata Memorial Hospital (Collaboration)
- Canadian Cancer Society (Collaboration)
- European Society of Gynaecological Oncology (ESGO) (Collaboration)
- Gustave-Roussy Institute (Collaboration)
- Pitié-Salpêtrière Hospital (Collaboration)
- Guangdong General Hospital (Collaboration)
- Herlev Hospital (Collaboration)
- UNIVERSITY OF DUNDEE (Collaboration)
- Antwerp University Hospital (Collaboration)
- KIDNEY RESEARCH UK (Collaboration)
- Virgen del Rocio University Hospital (Collaboration)
- Royal Marsden Hospital (Collaboration)
- Alcura (Collaboration)
- Germans Trias i Pujol University Hospital (Collaboration)
- Royal Sussex County Hospital (Collaboration)
- AstraZeneca (Collaboration)
- University College London Hospitals NHS Foundation Trust (Collaboration)
- University Hospital of Besancon (Collaboration)
- National Cancer Institute of Canada Clinical Trials Group (Collaboration)
- Research Group on Ovarian Cancer and Gynecologic Tumors of Mexico (GICOM) (Collaboration)
- Addenbrooke's Hospital (Collaboration)
- Cancer Trials Ireland (Collaboration)
- Clovis Oncology, inc (Collaboration)
- Regional Hospital San Camillo-Forlanini (Collaboration)
- Brighton and Sussex University Hospitals NHS Trust (Collaboration)
- University of Chicago (Collaboration)
- Irish Clinical Oncology Research Group (ICORG) (Collaboration)
- Essen University Hospital (Collaboration)
- National Cancer Research Institute (NCRI) (Collaboration)
- Istituti Fisioterapici Ospitalieri (Collaboration)
- IMPERIAL COLLEGE LONDON (Collaboration)
- Gynecologic Cancer InterGroup (GCIG) (Collaboration)
- Northern Centre For Cancer Care, Newcastle-upon-Tyne (Collaboration)
- European and American Osteosarcoma Study Group (EURAMOS) (Collaboration)
- University of Turin (Collaboration)
- N.N. Alexandrov National Cancer Centre of Belarus (Collaboration)
- Cooperative Osteosarcoma Study Group (Collaboration)
- EORTC (Collaboration)
- UNIVERSITY OF YORK (Collaboration)
- St Bartholomew's Hospital (Collaboration)
- USC Norris Cancer Hospital (Collaboration)
- University Medical Center Gronigen (Collaboration)
Publications
Ahmed HU
(2017)
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
in Lancet (London, England)
Ahmed M
(2016)
Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity.
in British journal of cancer
Alderson D
(2017)
Neoadjuvant chemotherapy in oesophageal adenocarcinoma - Authors' reply.
in The Lancet. Oncology
Allum WH
(2019)
Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction.
in The British journal of surgery
Andreassen CN
(2016)
Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.
in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Baumert BG
(2016)
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.
in The Lancet. Oncology
Bielack SS
(2015)
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial.
in Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Blinman PL
(2018)
Patients' preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile?
in Annals of oncology : official journal of the European Society for Medical Oncology
Bosaily AE
(2020)
Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study.
in European urology
| Guideline Title | NICE Guideline 2: Bladder cancer diagnosis and management |
| Description | Bladder Adj CT IPD (PMID: 16625650) NICE guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 16625650) |
| Guideline Title | AUA/ASCO/ASTRO/SUO Guideline treatment of non-metastatic muscle-invasive bladder cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) AUA/ASCO/ASTRO/SUO guideline 2017 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2015 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 15939530) |
| Guideline Title | Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2016 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2017 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2018 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Adj CT IPD (PMID:15939530) EAU guideline 2020 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2015 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Meta-analysis suggests a survival benefit to adjuvant therapy for pathologic T3, T4 or N+ disease at cystectomy"...."A meta-analysis of 6 trials found a 25% mortality reduction with adjuvant chemotherapy, but the authors pointed out several limitations of the data and concluded that evidence is insufficient for treatment", based on our systematic review and meta-analysis of IPD (PMID: 15939530) |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2017 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2018 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2019 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2020 Bladder Cancer |
| Description | Bladder Adj CT IPD (PMID:15939530) NCCN guideline 2020 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical Practice Guideline GU-013 Version 6 (Muscle Invasive Bladder Cancer) (2020) |
| Description | Bladder Adj CT IPD (PMID:16625650) AHS guideline 2020 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | CUA guideline: Muscle-invasive bladder cancer (2019) |
| Description | Bladder Neo CT IPD (PMID: 12801735) CUA guideline 2019 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Neo CT IPD (PMID: 12801735; 15939524) EAU guideline 2015 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Neoadjuvant cisplatin-containing combination chemotherapy improves OS (5-8% at 5 years)", based on our systematic review and meta-analysis of IPD (PMID:12801735; PMID:15939524) |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic (2019) |
| Description | Bladder Neo CT IPD (PMID: 12801735; 15939524) EAU guideline 2019 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic (2020) |
| Description | Bladder Neo CT IPD (PMID: 12801735; 15939524) EAU guideline 2020 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018) |
| Description | Bladder Neo CT IPD (PMID: 12801735; 15939524) SEOM guideline 2018 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial urinary bladder cancer |
| Description | Bladder Neo CT IPD (PMID: 12801735; 15939524) SOS/SUA guideline 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Neo CT IPD (PMID: 15939524) EAU guideline 2016 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guidelines on Bladder Cancer: Muscle-Invasive and Metastatic |
| Description | Bladder Neo CT IPD (PMID: 15939524) EAU guideline 2017 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 1.2015 |
| Description | Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | In a meta-analysis of 11 trials involving 3,005 patients, platinum-based neoadjuvant chemotherapy was associated with improved 5-year overall and disease-free survival (5% and 9% absolute improvement, respectively), based on our systematic review and meta-analysis of IPD (PMID: 15939524) |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 1.2017 |
| Description | Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 1.2018 |
| Description | Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 1.2019 |
| Description | Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - Bladder Cancer Version 1.2020 |
| Description | Bladder Neo CT IPD (PMID: 15939524) NCCN guideline 2020 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | SEOM clinical guidelines for the treatment of invasive bladder cancer (2016) |
| Description | Bladder Neo CT IPD (PMID: 15939524, PMID: 12801735) SEOM guideline 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical Practice Guideline GU-013 Version 6 (Muscle Invasive Bladder Cancer) (2020) |
| Description | Bladder Neo CT IPD (PMID:15846746) AHS Guideline 2020 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NICE Guideline 2: Bladder cancer diagnosis and management |
| Description | Bladder Neo CT IPD (PMID:15846746) NICE guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "One systematic review and meta-analysis of individual patient data (3,005 patients from 11 randomised trials) was identified (Advanced Bladder Cancer Meta-Analysis Collaboration (ABC), 2004). No other randomised trials were identified. High quality evidence about overall survival came from 10 trials with a total of 2,809 patients".....Recommendation: "Offer neoadjuvant chemotherapy using a cisplatin combination regimen before radical cystectomy or radical radiotherapy to people with newly diagnosed muscle-invasive urothelial bladder cancer for whom cisplatin-based chemotherapy is suitable. Ensure that they have an opportunity to discuss the risks and benefits with an oncologist who treats bladder cancer.", based on our systematic review and meta-analysis of IPD (PMID:15846746) |
| Guideline Title | UK guidelines for the management of bone sarcomas |
| Description | British Sarcoma Group: UK guidelines for the management of bone sarcomas (in BMC Clinical Sarcoma Research) |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Not known |
| URL | https://clinicalsarcomaresearch.biomedcentral.com/articles/10.1186/s13569-016-0047-1 |
| Guideline Title | Canadian Urologic Oncology Group guideline on Metastatic castration-naive and castration-sensitive prostate cancer |
| Description | Canadian Urological Association-2019 = STAMPEDE * 3:docetaxel, abiraterone and radiotherapy (2019) |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Change practice for patients with prostate cancer |
| URL | https://www.cua.org/themes/web/assets/files/6384_guideline_epub.pdf |
| Guideline Title | Cancer of the Uterine Cervix |
| Description | Cervix CTRT IPD (PMID:19001332) AHS guideline 2015 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Medically fit patients with advanced stage cervical cancer (stage IB2/IIB/IIIA/IIIB/IVA), as well as select stage IIA cases, should be considered for treatment with concurrent radiotherapy and chemotherapy.8,10,13,18 A meta-analysis of 13 trials showed that chemoradiotherapy (versus radiotherapy alone) increased the disease free survival rate at five years by eight percent.17 There was a significant trend towards increased overall survival with decreasing stage of disease (p = 0.017), with stage IA/IB/IIA patients achieving the lowest hazard ratio for death.", based on our systematic review and meta-analysis of IPD (PMID: 19001332) |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.2.2015 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A recent meta-analysis reported that chemoradiotherapy leads to a 6% improvement in 5-year survival (hazard ratio, 0.81; P <.001)", based on our systematic review and meta-analysis of IPD (PMID: 19001332) |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2016 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2016 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A recent meta-analysis reported that chemoradiotherapy leads to a 6% improvement in 5-year survival (hazard ratio, 0.81; P <.001)", based on our systematic review and meta-analysis of IPD (PMID: 19001332) |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2017 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2018 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.3.2019 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2019 (V3) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.5.2019 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2019 (V5) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2021 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:19001332) NCCN guideline 2021 (1) |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Cervix CTRT IPD (PMID:19001332) SEOM guideline 2015 |
| Description | Cervix CTRT IPD (PMID:19001332) SEOM guideline 2015 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Primary cisplatin-based chemo-radiotherapy is the treatment of choice in locally advanced cervical cancer (Level of evidence Ia; Recommendation level A)." For stages IB2, IIA2, IIB-IVA), based on our systematic review and meta-analysis of IPD (PMID: 19001332) |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2021 Cervical Cancer |
| Description | Cervix CTRT IPD (PMID:20091632) NCCN guideline 2021 (1) |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | CCO Guideline: Primary Treatment for Locally Advanced Cervical Cancer: Concurrent Platinum-based Chemotherapy and Radiation |
| Description | Cervix CTRT SR (PMID: 11564482) CCO guideline 2016 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | SEOM clinical guidelines for cervical cancer 2015 |
| Description | Cervix Neo CT IPD (PMID: 14602133) SEOM guideline 2015 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "To date, neoadjuvant chemotherapy before either standard concurrent chemo-radiation or radical surgery is not a standard approach (Level of evidence IIa; Category of recommendation C).", based on our systematic review and meta-analysis of IPD (PMID: 14602133) |
| Guideline Title | Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Cervix Neo CT IPD (PMID: 14602133)(PMID: 15106161) ESMO guideline 2017 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline |
| Description | Cervix Neo CT IPD (PMID: 15106161) ASCO guideline 2016 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Cervix Neo CT IPD (PMID: 19001332) ESMO guideline 2017 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.2.2015 Cervical Cancer |
| Description | Cervix Neo CT SR (PMID:20091632) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Although neoadjuvant chemotherapy followed by surgery has been used in areas where RT is not available, data suggest no improvement in survival when compared with surgery alone for early-stage cervical cancer", based on our systematic review and meta-analysis of summary data (PMID: 20091632) |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2016 Cervical Cancer |
| Description | Cervix Neo CT SR (PMID:20091632) NCCN guideline 2016 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Although neoadjuvant chemotherapy followed by surgery has been used in areas where RT is not available, data suggest no improvement in survival when compared with surgery alone for early-stage cervical cancer", based on our systematic review and meta-analysis of summary data (PMID: 20091632) |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2017 Cervical Cancer |
| Description | Cervix Neo CT SR (PMID:20091632) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.1.2018 Cervical Cancer |
| Description | Cervix Neo CT SR (PMID:20091632) NCCN guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.3.2019 Cervical Cancer |
| Description | Cervix Neo CT SR (PMID:20091632) NCCN guideline 2019 (V3) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.5.2019 Cervical Cancer |
| Description | Cervix Neo CT SR (PMID:20091632) NCCN guideline 2019 (V5) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Cancer of the Uterine Cervix |
| Description | Cervix Neo CT SR (PMID:23235641) AHS guideline 2015 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 23235641) |
| Guideline Title | Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline |
| Description | Cervix Neo CT SR (PMID:23235641) AHS guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Cervix Neo CT SR (PMID:23235641) ESMO guideline 2017 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Description | Cited in clinical guidelines - STAMPEDE (M1|RT comparison) - NHS England (Nov-2020) |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Building on the findings of STAMPEDE's "M1|RT comparison", at the start of Nov-2020, NHS England announced that it will now routinely commission "external beam radiotherapy for patients presenting with hormone sensitive, low volume metastatic prostate cancer at the time of diagnosis". This was considered by the Clinical Priorities Advisory Group (CPAG) in Jul-2020 to be a level 1 recommendation which means "high benefit" for "low cost". This makes the treatment available to all suitable patients |
| URL | https://www.england.nhs.uk/publication/external-beam-radiotherapy-for-patients-presenting-with-hormo... |
| Guideline Title | ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up (2018) |
| Description | Cited in clinical guidelines -- ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up (2018) |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://academic.oup.com/annonc/article/29/Supplement_4/iv79/5115250 |
| Guideline Title | BMJ Best Practice -- Osteosarcoma: The right clinical information, right where it's needed |
| Description | Cited in clinical guidelines -- EURAMOS-1 -- BMJ Best Practice (Feb-2019) |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://bestpractice.bmj.com/topics/en-gb/780/pdf/780.pdf |
| Guideline Title | Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 |
| Description | Colorectal Anti-EGFR SR (PMID:22118887) ASCO guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Guidelines Version 2.2015 Colon Cancer |
| Description | Colorectal Anti-EGFR SR (PMID:22118887) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A recent meta-analysis concluded there was a clear benefit to the use of EGFR inhibitors in patients with KRAS-wild-type metastatic colorectal cancer", based on our systematic review and meta-analysis of summary data (PMID: 22118887) |
| Guideline Title | Prostate cancer |
| Description | EAU, ESUR, ESTRO & SIOG Oncology Guidelines: Prostate Cancer 2019 = STAMPEDE * 3 papers:docetaxel, abiraterone and radiotherapy (2019) |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Joint guidelines from EAU = European Association of Urology ESTRO = European Society of Radiotherapy and Oncology ESUR = European Society of Urologic Radiotherapy SIOG = International Society of Geriatric Oncology |
| URL | https://www.sciencedirect.com/science/article/abs/pii/S0302283819301800?via%3Dihub |
| Guideline Title | S3-Leitlinie diagnostik, therapie und nachsorge der patientinnen mit endometrriumkarzinom |
| Description | Endometrial CT SR (PMID: 22895938) GGPO guideline 2017 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | S3-Leitlinie diagnostik, therapie und nachsorge der patientinnen mit endometrriumkarzinom |
| Description | Endometrial CT SR (PMID: 22895938) GGPO guideline 2018 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Endometrial cancer clinical practice guideline GYNE-002 |
| Description | Endometrial CT SR (PMID:17150999) AHS guideline 2015 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "..a meta-analysis by Humber, et al.in 2007 concluded that combination chemotherapy was superior to single agent chemotherapy, with the addition of anthracyclines and taxanes to cisplatin giving the best response.", based on our systematic review and meta-analysis of summary data (PMID: 17150999) |
| Guideline Title | CCO Guideline: Systemic Therapy for Advanced or Recurrent Endometrial Cancer, and Advanced or Recurrent Uterine Papillary Serous Carcinoma |
| Description | Endometrial CT SR (PMID:17150999) CCO guideline 2019 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2015. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Based on the current data, multiagent chemotherapy regimens are preferred for metastatic, recurrent, or high-risk disease, if tolerated", based on our systematic review and meta-analysis of summary data (PMID: 17150999) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2016. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline 2016 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Based on the current data, multiagent chemotherapy regimens are preferred for metastatic, recurrent, or high-risk disease, if tolerated", based on our systematic review and meta-analysis of summary data (PMID: 17150999) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2017. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1 2018. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3 2019. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4 2019. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline 2019 (V4) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1 2021. Uterine Neoplasms |
| Description | Endometrial CT SR (PMID:17150999) NCCN guideline 2021 (V1) |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Adjuvant Systemic Chemotherapy, Following Surgery and External Beam Radiotherapy, for Adults with Newly Diagnosed Malignant Glioma |
| Description | Glioma CT IPD (PMID:11937180) CCO guideline 2013 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2015 Central Nervous System Cancers |
| Description | Glioma CT IPD (PMID:11937180) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "In contrast, 2 meta-analyses reviewed data from randomized trials of high-grade glioma patients, and both found a modest survival benefit when chemotherapy was added to postoperative RT. Specifically, the Glioma Meta- Analysis Trialists Group reviewed 12 studies involving approximately 3000 patients and reported an absolute increase in 1-year survival from 40% to 46% and a 2-month increase in median survival when chemotherapy was added to postoperative RT (HR, 0.85; 95% CI, 0.78- 0.91; P < .0001)", based on our systematic review and meta-analysis of IPD (PMID:11937180) |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2017 Central Nervous System Cancers |
| Description | Glioma CT IPD (PMID:11937180) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology - v.1.2017 Central Nervous System Cancers |
| Description | Glioma CT IPD (PMID:11937180) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung Adj CT IPD (PMID: 20338628) CCA guideline stage III Adj CT operable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung Adj CT IPD (PMID: 20338628) CCA guideline stage III Adj CT operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung Adj CT IPD (PMID: 20338628) CCA guideline stage III NeoAdj CT operable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung Adj CT IPD (PMID: 20338628) CCA guideline stage III NeoAdj CT operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: An American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline |
| Description | Lung Adj CT IPD (PMID:20338628) ASTRO guideline Def Adj RT 2015 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Currently, adjuvant CT has become the standard of care for patients with completely resected stage II and III NSCLC, after the results from multiple randomized trials, later validated by meta-analyses,demonstrated that addition of platinum-based CT after resection of LA NSCLC leads to absolute overall survival improvements at 5 years of between 5% and 15%", based on our systematic review and meta-analysis of IPD (PMID: 20338628) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC? |
| Description | Lung Adj CT IPD (PMID:20338628) CCA guideline stage II CT after operable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of postoperative radiotherapy (PORT) in the treatment of resected stage III NSCLC? |
| Description | Lung Adj CT IPD (PMID:20338628) CCA guideline stage III PORT resected 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20338628) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of postoperative radiotherapy (PORT) in the treatment of resected stage III NSCLC? |
| Description | Lung Adj CT IPD (PMID:20338628) CCA guideline stage III PORT resected 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the role of chemotherapy after surgery in the treatment of operable stage III NSCLC? |
| Description | Lung Adj CT IPD (PMID:20338628) CCA guideline stage III operable NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Postoperative adjuvant systemic therapy in completely resected non-small cell lung cancer. Guideline 7-1-2 Version 2 |
| Description | Lung Adj CT IPD (PMID:20338628) CCO guideline post-op tx after operable 2016 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Key Evidence for recommendation 1"..... "An individual patient analysis of 26 randomized controlled trials (RCTs) demonstrated a significant survival benefit in patients receiving adjuvant chemotherapy compared with the observation group (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.81 to 0.92; p<0.0001) representing an absolute improvement of 4% (95% CI, 3 to 6) at five years.", based on our systematic review and meta-analysis of IPD (PMID: 20338628) |
| Guideline Title | Early-Stage and Locally Advanced (non-metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines |
| Description | Lung Adj CT IPD (PMID:20338628) ESMO guideline 2017 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The NCCN Panel recommends chemotherapy (category 1) for patients with negative surgical margins and stage II disease, including 1) T1ab- 2a, N1; 2) T2b, N1; or 3) T3, N0 disease", based on our systematic review and meta-analysis of IPD (PMID: 20338628) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2016 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The NCCN Panel recommends chemotherapy (category 1) for patients with negative surgical margins and stage II disease, including 1) T1ab- 2a, N1; 2) T2b, N1; or 3) T3, N0 disease"..."Postoperative adjuvant sequential chemotherapy with RT is recommended for patients with T1-3, N2 disease and negative margins . A meta-analysis assessed postoperative chemotherapy with (or without) postoperative RT in patients mainly with stage III disease.675 In this meta-analysis, 70% of the eligible trials used adjuvant chemotherapy before RT; 30% used concurrent chemo/RT. Regimens included cisplatin/vinorelbine followed by RT or concurrent cisplatin/etoposide.", based on our systematic review and meta-analysis of IPD (PMID: 20338628) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2019. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2020. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2020 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2021. Non-Small Cell Lung Cancer |
| Description | Lung Adj CT IPD (PMID:20338628) NCCN guideline 2021 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018) |
| Description | Lung Adj CT IPD (PMID:20338628, 25730344) SEOM guideline 2018 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: ASCO Clinical Practice Guideline Update |
| Description | Lung Adj CT IPD (PMID:25730344) ASCO guideline 2017 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the role of chemotherapy after surgery in the treatment of operable stage I NSCLC? |
| Description | Lung Adj CT IPD (PMID:25730344) CCA guideline stage I operable NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC? |
| Description | Lung Adj CT IPD (PMID:25730344) CCA guideline stage II operable NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Lung Adj CT IPD (PMID:25730344)(PMID: 20338628) CCA guideline stage II CT after operable 2016 |
| Description | Lung Adj CT IPD (PMID:25730344)(PMID: 20338628) CCA guideline stage II CT after operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Lung CT 95 IPD (PMID: 20464750, 18678835) ESMO guideline metastatic NSCLC 2019 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | ASCO Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) ASCO guideline stage I-III NSCLC 2017 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: An American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline |
| Description | Lung CT 95 IPD (PMID:7580546) ASTRO guideline Def Adj RT 2015 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline inoperable stage III 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline inoperable stage IV 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline operable stage II 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline operable stage III 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT after operable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT after operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT before operable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline stage II CT before operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline stage III Adj CT operable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 7580546) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline stage III Adj CT operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline stage III GoodPS inoperable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "In good performance status patients with inoperable stage III NSCLC, the addition of chemotherapy to radiation therapy is associated with a statistically significant survival benefit compared with radiation therapy alone", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline stage III GoodPS inoperable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline stage IV 1stLineCT inoperable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Platinum-based chemotherapy improves survival in stage IV NSCLC compared with best supportive care. Note that this evidence is based on clinical trials conducted in fit patients, with predominant performance status 0-1, no unstable co-morbidities, adequate organ function and without uncontrolled brain metastases.", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC? |
| Description | Lung CT 95 IPD (PMID:7580546) CCA guideline stage IV 1stLineCT inoperable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Evidence-based recommendations for the management of non-small cell lung cancer (NSCLC) |
| Description | Lung CT 95 IPD (PMID:7580546) CCMB guideline 2015 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "There is level I evidence for patients to receive platinum-based post-surgical adjuvant chemotherapy in II and IIIA NSCLC", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| Guideline Title | Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Lung CT 95 IPD (PMID:7580546) ESMO guideline metastatic NSCLC 2019 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines |
| Description | Lung CT 95 IPD (PMID:7580546) ESMO guideline stage M1 NSCLC 2016 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines |
| Description | Lung CT 95 IPD (PMID:7580546) ESMO guideline stage M1 NSCLC 2016 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2017 |
| Description | Lung CT 95 IPD (PMID:7580546) GGPO guideline 2017 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2018 |
| Description | Lung CT 95 IPD (PMID:7580546) GGPO guideline 2018 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2016 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial", based on our systematic review and meta-analysis of IPD (PMID: 7580546) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2018. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2019. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2020. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2020 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2021. Non-Small Cell Lung Cancer |
| Description | Lung CT 95 IPD (PMID:7580546) NCCN guideline 2021 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung Neo CT IPD (PMID: 24576776) CCA guideline stage III NeoAdj CT operable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "In patients with clinical stage IIIA disease treated by surgery, neoadjuvant chemotherapy reduces the relative risk of death by 13%, and improves absolute 5 year survival rates from 20 to 25%"; "It is recommended to consider pre-operative administration of 2-3 cycles of platinum doublet-based, third-generation chemotherapy as a treatment option in good performance status patients with operable clinical stage IIIA non-small cell lung cancer.", based on our systematic review and meta-analysis of IPD (PMID: 24576776) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung Neo CT IPD (PMID: 24576776) CCA guideline stage III NeoAdj CT operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Early-Stage and Locally Advanced (non-metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines |
| Description | Lung Neo CT IPD (PMID: 24576776) ESMO guideline 2017 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2017 |
| Description | Lung Neo CT IPD (PMID: 24576776) GGPO guideline 2018 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2018 |
| Description | Lung Neo CT IPD (PMID: 24576776) GGPO guideline 2018 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer |
| Description | Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The NCCN Guidelines state that patients with stage II or IIIA (T3, N1) disease may be treated with induction chemotherapy before surgery if they are candidates for adjuvant therapy after surgery", based on our systematic review and meta-analysis of IPD (PMID: 24576776) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer |
| Description | Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2016 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The NCCN Guidelines state that patients with stage II or IIIA (T3, N1) disease may be treated with induction chemotherapy before surgery if they are candidates for adjuvant therapy after surgery", based on our systematic review and meta-analysis of IPD (PMID: 24576776) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer |
| Description | Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2018. Non-Small Cell Lung Cancer |
| Description | Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2019. Non-Small Cell Lung Cancer |
| Description | Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2020. Non-Small Cell Lung Cancer |
| Description | Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2020 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2021. Non-Small Cell Lung Cancer |
| Description | Lung Neo CT IPD (PMID: 24576776) NCCN guideline 2021 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung Neo CT SR (PMID: 17636828) CCA guideline stage III Adj CT operable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17636828) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of adjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung Neo CT SR (PMID: 17636828) CCA guideline stage III Adj CT operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung Neo CT SR (PMID: 17636828) CCA guideline stage III NeoAdj CT operable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17636828) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung Neo CT SR (PMID: 17636828) CCA guideline stage III NeoAdj CT operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015 |
| Description | Lung Neo CT SR (PMID: 17636828) SEOM guideline 2015 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The Cochrane meta-analysis demonstrated that preoperative therapy is better than surgery alone for patients with stage III", based on our systematic review and meta-analysis of summary data (PMID: 17636828) |
| Guideline Title | SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018) |
| Description | Lung Neo CT SR (PMID: 17636828) SEOM guideline 2018 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage I NSCLC? |
| Description | Lung Neo CT SR (PMID:17409927) CCA guideline stage I CT before operable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage I NSCLC? |
| Description | Lung Neo CT SR (PMID:17409927) CCA guideline stage I CT before operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the role of chemotherapy before surgery in the treatment of operable stage I NSCLC? |
| Description | Lung Neo CT SR (PMID:17409927) CCA guideline stage I operable NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC? |
| Description | Lung Neo CT SR (PMID:17409927) CCA guideline stage II CT before operable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as evidence in this guideline (PMID: 17409927) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC? |
| Description | Lung Neo CT SR (PMID:17409927) CCA guideline stage II CT before operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC? |
| Description | Lung Neo CT SR (PMID:17409927) CCA guideline stage II operable NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung Neo CT SR (PMID:17636828) CCA guideline stage III operable NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC? |
| Description | Lung Neo CT SR (PMID:24576776) CCA guideline stage II CT before operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the role of chemotherapy before surgery in the treatment of operable stage II NSCLC? |
| Description | Lung Neo CT SR (PMID:24576776) CCA guideline stage II operable NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the clinical benefit of neoadjuvant chemotherapy for patients with stage III operable NSCLC? |
| Description | Lung Neo CT SR (PMID:24576776) CCA guideline stage III operable NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | CCO Guideline:Use of Preoperative Chemotherapy with or without Postoperative Radiotherapy in Technically Resectable Stage IIIA Non-Small Cell Lung Cancer #7-4 V2 |
| Description | Lung Neo CT SR (PMID:24576776) CCO guideline 2017 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2017 |
| Description | Lung PORT IPD (PMID: 9690404) GGPO guideline 2017 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2018 |
| Description | Lung PORT IPD (PMID: 9690404) GGPO guideline 2018 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID: 9690404) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 9690404) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID: 9690404) NCCN guideline 2016 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "PORT is not recommended for patients with pathologic stage N0-1 disease, because it has been associated with increased mortality, at least when using older RT techniques" , based on our systematic review and meta-analysis of IPD (PMID: 9690404) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2018. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID: 9690404) NCCN guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2019. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID: 9690404) NCCN guideline 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2020. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID: 9690404) NCCN guideline 2020 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2021. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID: 9690404) NCCN guideline 2021 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer |
| Description | Lung PORT IPD (PMID: 9690404; 15603857) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Evidence-based recommendations for the management of non-small cell lung cancer (NSCLC) |
| Description | Lung PORT IPD (PMID: 9690404; 15846628) CCMB guideline 2015 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Post-operative radiation therapy is not recommended as a standard of practice following complete resection of stage I and II NSCLC", based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15846628) |
| Guideline Title | Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: An American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline |
| Description | Lung PORT IPD (PMID: 9690404; 15846628; 15603857) ASTRO guideline Def Adj RT 2015 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Phase III studies and meta-analyses of PORT in completely resected (R0) LA NSCLC with N0-1 disease demonstrate inferior survival when compared to observation strategies; therefore, PORT therapy for this patient population is not routinely recommended.", based on our systematic review and meta-analysis of IPD (PMID: 9690404; PMID: 15846628; PMID: 15603857) |
| Guideline Title | Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: ASCO Clinical Practice Guideline Update |
| Description | Lung PORT IPD (PMID: 9690404; 23453644) ASCO guideline 2017 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the role of radiotherapy after surgery in the treatment of operable stage I NSCLC? |
| Description | Lung PORT IPD (PMID:15846628) CCA guideline operable stage I NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the role of radiotherapy after surgery in the treatment of operable stage II NSCLC? |
| Description | Lung PORT IPD (PMID:15846628) CCA guideline operable stage II NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the role of postoperative radiotherapy (PORT) in resected stage III NSCLC? |
| Description | Lung PORT IPD (PMID:15846628) CCA guideline operable stage III NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of radiotherapy after surgery in the treatment of operable stage I NSCLC? |
| Description | Lung PORT IPD (PMID:15846628) CCA guideline stage I RT after operable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "There is strong evidence, based on an individual patient data meta-analysis and recently updated, that the use of postoperative radiotherapy following complete resection of stage I NSCLC is detrimental, and is associated with worse survival. In patients who have had complete resection of stage I NSCLC, postoperative radiotherapy is not recommended", based on our systematic review and meta-analysis of IPD (PMID: 15846628) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer: What is the role of radiotherapy after surgery in the treatment of operable stage I NSCLC? |
| Description | Lung PORT IPD (PMID:15846628) CCA guideline stage I RT after operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of radiotherapy after surgery in the treatment of operable stage II NSCLC? |
| Description | Lung PORT IPD (PMID:15846628) CCA guideline stage II RT after operable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "In patients who have had complete resection of stage II NSCLC, postoperative radiotherapy is not recommended", based on our systematic review and meta-analysis of IPD (PMID: 15846628) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of radiotherapy after surgery in the treatment of operable stage II NSCLC? |
| Description | Lung PORT IPD (PMID:15846628) CCA guideline stage II RT after operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of postoperative radiotherapy (PORT) in the treatment of resected stage III NSCLC? |
| Description | Lung PORT IPD (PMID:15846628) CCA guideline stage III PORT resected 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A meta-analysis demonstrates no clear evidence of an adverse or beneficial effect of PORT on survival in patients with pN2 disease", based on our systematic review and meta-analysis of IPD (PMID: 15846628) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of postoperative radiotherapy (PORT) in the treatment of resected stage III NSCLC? |
| Description | Lung PORT IPD (PMID:15846628) CCA guideline stage III PORT resected 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Early-Stage and Locally Advanced (non-metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines |
| Description | Lung PORT IPD (PMID:15846628) ESMO guideline 2017 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015 |
| Description | Lung PORT IPD (PMID:15846628) SEOM guideline 2015 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "PORT is not recommended for patients with completely resected stage I-II NSCLC (IA and IIA, respectively)", based on our systematic review and meta-analysis of IPD (PMID: 15846628) |
| Guideline Title | Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2017 |
| Description | Lung SC IPD (PMID: 18678835) GGPO guideline 2017 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2018 |
| Description | Lung SC IPD (PMID: 18678835) GGPO guideline 2018 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial", based on our systematic review and meta-analysis of IPD (PMID: 18678835) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2016 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "For patients with stage IV disease who have a good PS, platinum-based chemotherapy is beneficial", based on our systematic review and meta-analysis of IPD (PMID: 18678835) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2018. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2019. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2020. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2020 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2021. Non-Small Cell Lung Cancer |
| Description | Lung SC IPD (PMID: 18678835) NCCN guideline 2021 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018) |
| Description | Lung SC IPD (PMID: 18678835) SEOM guideline 2018 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update |
| Description | Lung SC IPD (PMID: 20464750) ASCO guideline systemic Stage IV 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Cochrane systematic review on chemotherapy and supportive care... continued to show that chemotherapy and best supportive care versus supportive care alone benefit patients, including those who have PS 2", based on our systematic review and meta-analysis of IPD (PMID: 20464750) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC? |
| Description | Lung SC IPD (PMID: 20464750) CCA guideline stage II CT after operable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20464750) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC? |
| Description | Lung SC IPD (PMID: 20464750) CCA guideline stage II CT after operable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the role of chemotherapy after surgery in the treatment of operable stage II NSCLC? |
| Description | Lung SC IPD (PMID: 20464750) CCA guideline stage II CT operable NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC? |
| Description | Lung SC IPD (PMID: 20464750) CCA guideline stage IV 1stLineCT inoperable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Platinum-based chemotherapy improves survival in stage IV NSCLC compared with best supportive care. Note that this evidence is based on clinical trials conducted in fit patients, with predominant performance status 0-1, no unstable co-morbidities, adequate organ function and without uncontrolled brain metastases.", based on our systematic review and meta-analysis of IPD (PMID: 20464750) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC? |
| Description | Lung SC IPD (PMID: 20464750) CCA guideline stage IV 1stLineCT inoperable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the optimal first-line chemotherapy regimen in patients with stage IV inoperable NSCLC? |
| Description | Lung SC IPD (PMID: 20464750) CCA guideline stage IV inoperable NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy when added to radiotherapy in the treatment of inoperable stage II NSCLC? |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage II CTRT inoperable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20351327) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the role of chemotherapy when added to radiotherapy in the treatment of inoperable stage II NSCLC? |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage II CTRT inoperable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the role of chemotherapy when added to radiotherapy in the treatment of inoperable stage II NSCLC? |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage II inoperable NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease? |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage III GoodPS inoperable 2015 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "For patients with good performance status and inoperable stage III NSCLC, the concurrent administration of chemotherapy and radiotherapy is recommended.", based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| Guideline Title | Clinical practice guidelines for the treatment of lung cancer. What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease? |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage III GoodPS inoperable 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | What is the recommended treatment approach for the definitive management of patients with good performance status and inoperable stage III disease? |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) CCA guideline stage III inoperable NSCLC 2018 |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | CCO Guideline:Use of Preoperative Chemotherapy with or without Postoperative Radiotherapy in Technically Resectable Stage IIIA Non-Small Cell Lung Cancer #7-4 V2 |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) CCO guideline 2017 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Early-Stage and Locally Advanced (non-metastatic) Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) ESMO guideline 2017 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2017 |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) GGPO guideline 2017 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Konsultationsfassung S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms V1: 2018 |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) GGPO guideline 2018 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2015. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Concurrent chemoradiation is superior to sequential therapy for patients with unresectable stage III disease" "When distant metastases are not present, the NCCN Panel recommends that the patient be treated with definitive concurrent chemoradiation therapy" , based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2016. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2016 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The standard of care for patients with inoperable stage II (node positive) and stage III is concurrent chemotherapy/RT" "Concurrent chemoradiation is superior to sequential therapy for patients with unresectable stage III disease." "When distant metastases are not present, the NCCN Panel recommends that the patient be treated with definitive concurrent chemoradiation therapy" , based on our systematic review and meta-analysis of IPD (PMID: 20351327) |
| Guideline Title | NCCN Practice Guidelines in Oncology v.2.2018. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.4.2017. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.3.2019. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v.1.2020. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2020 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology v2.2021. Non-Small Cell Lung Cancer |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) NCCN guideline 2021 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015 |
| Description | Lung SeqCon CTRT IPD (PMID:20351327) SEOM guideline 2015 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as evidence in this guideline (PMID: 20351327) |
| Description | Membership of Psycho-social oncology and survivorship NCRI CSG |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) Hodgkin Lymphoma Version 1.2018 - December 20, 2017 |
| Description | NCCN guideline 2017 - Hodgkin lymphoma - LY09 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.nccn.org/professionals/physician_gls/pdf/hodgkin_blocks.pdf |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology -- Prostate Cancer (v1.2019 -- 06-Mar-2019) |
| Description | NCCN guidelines (updated Mar-2019) - PR07 (4 papers) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology -- Prostate Cancer (v1.2019 -- 06-Mar-2019) |
| Description | NCCN guidelines (updated Mar-2019) - RT01 (1 paper) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf |
| Guideline Title | NICE guidance 2018 for management of brain tumours |
| Description | NICE guidance 2018 for management of brain tumours |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | The MRC/CRUK/EORTC trial established the improvement in survival at 5 years related to the use of chemotherapy |
| URL | https://www.nice.org.uk/guidance/ng99/chapter/Recommendations#management-of-glioma |
| Guideline Title | Prostate cancer: diagnosis and management [A] Evidence review for bisphosphonates |
| Description | NICE guidelines on bisphosphonates: STAMPEDE, PR05 (6 papers) (2019) |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | No changes to treatment |
| URL | https://www.nice.org.uk/guidance/ng131/evidence/a-bisphosphonates-pdf-6779081774 |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology Bone Cancer |
| Description | National Comprehensive Cancer Network - EURAMOS-1 Good Responders |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Not known |
| URL | https://emedicine.medscape.com/article/1256857-guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology Bone Cancer |
| Description | National Comprehensive Cancer Network - EURAMOS-1 Poor Responders |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://emedicine.medscape.com/article/1256857-guidelines |
| Guideline Title | Leitlinienprogramm onkologie. Diagnostik und therapie des Ösophaguskarzinoms v1.0 2015 |
| Description | Oesophagus RT IPD (PMID:16235286) GGPO guideline 2015 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "Eine alleinige präoperative Strahlentherapie kann beim operablen Patienten mit einem resektablen Ösophaguskarzinom nicht empfohlen werden.", based on our systematic review and meta-analysis of IPD (PMID: 16235286) |
| Guideline Title | Leitlinienprogramm onkologie. Diagnostik und therapie des Ösophaguskarzinoms v2.0 2018 |
| Description | Oesophagus RT IPD (PMID:16235286) GGPO guideline 2018 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Evidence-based recommendations for the management of potentially curable esophageal carcinoma |
| Description | Oesophagus RT IPD (PMID:9635705) CCMB guideline 2015 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of IPD was cited as key evidence in this guideline (PMID: 9635705) |
| Guideline Title | NCCN Guidelines Version 3.2015 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "A meta-analysis from the Oesophageal Cancer Collaborative Group also showed no clear evidence of a survival advantage with preoperative radiation", based on our systematic review and meta-analysis of IPD. (PMID: 9635705) |
| Guideline Title | NCCN Guidelines Version 3.2016 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2016 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Guidelines Version 4.2017 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Guidelines Version 2.2018 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Guidelines Version 3.2019 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Guidelines Version 5.2020 Esophageal and Esophagogastric Junction Cancers |
| Description | Oesophagus RT IPD (PMID:9635705) NCCN guideline 2020 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der ver-schiedenen Stadien des Prostatakarzinoms (2019) |
| Description | PROMIS results cited in Germal Guideline Program in Oncology |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Prostata_5_0/... |
| Guideline Title | Prostate cancer: diagnosis and management |
| Description | PROMIS results cited in NICE Guideline 2019 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.nice.org.uk/guidance/ng131/evidence/d-diagnosing-and-identifying-clinically-significant-... |
| Guideline Title | Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline |
| Description | Prostate ABI SR (PMID: 28800492) ASCO guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU-ESTRO-ESUR-SIOG GUIDELINES ON PROSTATE CANCER |
| Description | Prostate ABI SR (PMID: 28800492) EAU guideline 2018 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2020) |
| Description | Prostate Abi AD (PMID: 28800492) EAU guideline 2020 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2020) |
| Description | Prostate Artistic AD (PMID: 33002431) EAU guideline 2020 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.3.2020 Prostate Cancer |
| Description | Prostate Artistic AD (PMID: 33002431) NCCN guideline 2020 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 |
| Description | Prostate CT AD (PMID: 26718929) APCC consensus 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Prostate CT AD (PMID: 26718929) ESMO guideline 2020 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | St Gallens Consensus 2017. Management of Patients with Advanced Prostate Cancer:The Report of the Advanced Prostate Cancer Consensus |
| Description | Prostate CT SR (PMID: 26718929) APCC Consensus 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline |
| Description | Prostate CT SR (PMID: 26718929) ASCO guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU-ESTRO-ESUR-SIOG Guidelines on prostate cancer |
| Description | Prostate CT SR (PMID: 26718929) EAU guideline 2017 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU-ESTRO-ESUR-SIOG GUIDELINES ON PROSTATE CANCER |
| Description | Prostate CT SR (PMID: 26718929) EAU guideline 2018 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2019) |
| Description | Prostate CT SR (PMID: 26718929) EAU guideline 2019 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der ver-schiedenen Stadien des Prostatakarzinoms |
| Description | Prostate CT SR (PMID: 26718929) GGPO guideline 2017 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der ver-schiedenen Stadien des Prostatakarzinoms |
| Description | Prostate CT SR (PMID: 26718929) GGPO guideline 2019 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | JUA Evidence-based clinical practice guideline for prostate cancer |
| Description | Prostate CT SR (PMID: 26718929) JUA guideline 2017 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.4.2018 Prostate Cancer |
| Description | Prostate CT SR (PMID: 26718929) NCCN guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.4.2019 Prostate Cancer |
| Description | Prostate CT SR (PMID: 26718929) NCCN guideline 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Practice Guidelines in Oncology - v.3.2020 Prostate Cancer |
| Description | Prostate CT SR (PMID: 26718929) NCCN guideline 2020 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | SEOM clinical guidelines for the treatment of metastatic prostate |
| Description | Prostate CT SR (PMID: 26718929) SEOM guideline 2017 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2019) |
| Description | Prostate Network AD (PMID: 29788164) EAU guideline 2019 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2020) |
| Description | Prostate Network AD (PMID: 29788164) EAU guideline 2020 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Description | Prostate Network AD (PMID: 29788164) ESMO guideline 2020 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 |
| Description | Prostate RT AD (PMID: 30826218) APCC consensus 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | EAU Guideline: Prostate Cancer (2020) |
| Description | Prostate RT AD (PMID: 30826218) EAU guideline 2020 |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | CUA guideline-Canadian Urologic Oncology Group guideline on Metastatic castration-naive and castration-sensitive prostate cancer |
| Description | Prostate RT SR (PMID: 30826218) CUA guideline 2019 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | Lung cancer |
| Description | QUARTZ results cited in Cancer Care Australia guidelines |
| Geographic Reach | Australia |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://wiki.cancer.org.au/australia/Clinical_question:What_is_the_clinical_benefit_of_radiotherapy_... |
| Guideline Title | METASTATIC NON-SMALL-CELL LUNG CANCER: ESMO CLINICAL PRACTICE GUIDELINES FOR DIAGNOSIS, TREATMENT AND FOLLOW-UP |
| Description | QUARTZ results cited in ESMO guidelines |
| Geographic Reach | Europe |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.esmo.org/Guidelines/Lung-and-Chest-Tumours/Metastatic-Non-Small-Cell-Lung-Cancer |
| Guideline Title | S3-Leitlinie Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms |
| Description | QUARTZ results cited in German Guideline Program in Oncology guidelines |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Lungenkarzino... |
| Guideline Title | Non-small cell lung cancer |
| Description | QUARTZ results cited in NCCN guidelines |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| URL | https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf |
| Guideline Title | BCCA Musculoskeletal & Sarcoma Guideline |
| Description | Sarcoma CT IPD (PMID:9400508) BCCA guideline 2018 |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.1.2015 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The Sarcoma Meta Analysis Collaboration (SMAC) performed a meta-analysis of 14 randomized trials (1,568 patients) which compared adjuvant chemotherapy to follow-up and in some cases RT after surgery with a variety of sarcomas. The result of the meta-analysis showed that doxorubicin-based chemotherapy prolongs local and distant recurrence and overall RFS in adults with localized, resectable STS of the extremity and was associated with decreased recurrence rates. The OS advantage was not significant, although there was a trend in favor of postoperative chemotherapy", based on our systematic review and meta-analysis of IPD (PMID: 9400508) |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.1.2016 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN guideline 2016 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | "The Sarcoma Meta Analysis Collaboration (SMAC) performed a meta-analysis of 14 randomized trials (1,568 patients) which compared adjuvant chemotherapy to follow-up and in some cases RT after surgery with a variety of sarcomas. The result of the meta-analysis showed that doxorubicin-based chemotherapy prolongs local and distant recurrence and overall RFS in adults with localized, resectable STS of the extremity and was associated with decreased recurrence rates. The OS advantage was not significant, although there was a trend in favor of postoperative chemotherapy", based on our systematic review and meta-analysis of IPD (PMID: 9400508) |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.1.2017 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2019 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN guideline 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v4.2019 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN guideline 2019 (V4) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v1.2021 Soft Tissue Sarcoma |
| Description | Sarcoma CT IPD (PMID:9400508) NCCN guideline 2021 (V1) |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | UK guidelines for the management of soft tissue sarcomas |
| Description | Sarcoma CT IPD (PMID:9400508, PMID: 10796873) BSG guideline 2016 |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.1.2015 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2015 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as key evidence in this guideline (PMID: 7640234) |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.1.2016 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2016 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Our systematic review and meta-analysis of summary data was cited as key evidence in this guideline (PMID: 7640234) |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.1.2017 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2017 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.1.2018 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.1.2018 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2018 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.2.2019 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2019 |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.4.2019 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2019 (V4) |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN Clinical Practice Guidelines in Oncology v.1.2021 Soft Tissue Sarcoma |
| Description | Sarcoma CT SR (PMID:7640234) NCCN guideline 2021 (V1) |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Guideline Title | NCCN prostate cancer guidelines |
| Description | US National Comprehensive Cancer Network = STAMPEDE * 3: docetaxel, abiraterone & radiotherapy (2019) |
| Geographic Reach | North America |
| Policy Influence Type | Citation in clinical guidelines |
| Impact | Change practice for patients with prostate cancer |
| URL | https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf |
| Description | AstraZeneca support for start-up of RAMPART renal cancer adjuvant trial |
| Amount | £694,715 (FKP) |
| Organisation | AstraZeneca |
| Sector | Private |
| Country | United Kingdom |
| Start | 03/2016 |
| End | 12/2017 |
| Description | Building The Clinical Research Ecosystem |
| Amount | $329,253 (USD) |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 11/2017 |
| End | 09/2020 |
| Description | CRUK / CTAAC funding for EURAMOS-1 --> U122861384 (one of many co-funders for many destinations --> approx UK total shown) |
| Amount | £500,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 05/2005 |
| End | 06/2014 |
| Description | CTAAC funding for Add-Aspirin |
| Amount | £3,598,674 (GBP) |
| Funding ID | C471/A15015 |
| Organisation | Cancer Research UK |
| Department | CTAAC Clinical Trials Advisory & Awards |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2013 |
| End | 12/2023 |
| Description | CTAAC funding for Add-Aspirin sample collection |
| Amount | £404,910 (GBP) |
| Funding ID | C471/A19252 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2015 |
| End | 06/2025 |
| Description | CTAAC funding for PATCH extension |
| Amount | £1,288,426 (GBP) |
| Funding ID | C17093/A12443 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2010 |
| End | 03/2021 |
| Description | Clinical Research Committee - funding extension for TRISST trial |
| Amount | £228,700 (GBP) |
| Funding ID | C17084/A8690 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2017 |
| End | 03/2021 |
| Description | Clinical Trial Fellowship at the MRC Clinical Trials Unit, UCL |
| Amount | £97,022 (GBP) |
| Funding ID | 26413 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2021 |
| Description | European Science Foundation funding for EURAMOS-1 --> U122861384 (one of many co-funders for many destinations --> approx UK total shown) |
| Amount | £500,000 (GBP) |
| Funding ID | CRUK/06/019 [A3804] - Cancer Research UK seems to consider this as one with the original grant. We did not expect this. |
| Organisation | European Science Foundation (ESF) |
| Sector | Charity/Non Profit |
| Country | France |
| Start | 01/2005 |
| End | 12/2019 |
| Description | GCRF UCL internal small grant for building clinical trials capacity in India |
| Amount | £75,878 (GBP) |
| Organisation | University College London |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 06/2020 |
| Description | IMPART: Affordable Approaches to Cancer, Seed Funding |
| Amount | £30,000 (GBP) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 12/2020 |
| Description | MRC research grant - the Re-IMAGINE consortium |
| Amount | £6,347,795 (GBP) |
| Funding ID | MR/R014043/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2018 |
| End | 05/2022 |
| Description | MRC trial funding grant for EURAMOS-1 --> U122861384 (one of many co-funders for many destinations --> approx UK total shown) |
| Amount | £500,000 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2005 |
| End | 06/2015 |
| Description | NIHR (HTA) funding for Add-Aspirin |
| Amount | £3,124,812 (GBP) |
| Funding ID | 12/01/38 |
| Organisation | National Institute for Health Research |
| Department | Health Technology Assessment Programme (HTA) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2014 |
| End | 04/2023 |
| Description | PROMIS trial |
| Amount | £1,786,862 (GBP) |
| Funding ID | 09/22/67 |
| Organisation | National Institute for Health Research |
| Department | Health Technology Assessment Programme (HTA) |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2011 |
| End | 11/2015 |
| Description | Population Research Committee - Catlyst Award |
| Amount | £5,035,497 (GBP) |
| Funding ID | C569/A24991 |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2018 |
| End | 01/2023 |
| Description | Prostate Cancer Charity -- RT01/PR07/The Prostate Cancer Charity, UK (via Institute of Cancer Research) |
| Amount | £10,000 (GBP) |
| Organisation | Prostate Cancer UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2010 |
| End | 12/2014 |
| Description | RADICALS extension (A7829/A6381) |
| Amount | £325,000 (GBP) |
| Funding ID | (A7829/A6381) |
| Organisation | Cancer Research UK |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 03/2023 |
| Description | RAMPART Clinical Trial - Collaboration with AZ |
| Amount | $22,000,000 (USD) |
| Organisation | AstraZeneca |
| Department | Astra Zeneca |
| Sector | Private |
| Country | United States |
| Start | 05/2018 |
| End | 12/2029 |
| Description | REFINE: Reduced frequency immune checkpoint inhibition, a basket trial |
| Amount | £1,061,788 (GBP) |
| Organisation | J P Moulton Charitable Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2020 |
| End | 05/2024 |
| Title | Add-Aspirin sample collection |
| Description | Participants in the Add-Aspirin trial are being asked to provide blood and tumour samples at the time of registration in the trial. Samples are being collected at two central laboratories. The collection was initiated when the trial opened to recruitment (October 2015) and is currently ongoing. This will provide a unique and valuable resource for future translational research, and a broad programme of work utilising the samples is being planned, including investigation of the mechanisms of action responsible for anti-cancer effects of aspirin and identification of biomarkers for aspirin efficacy and toxicity in this setting. |
| Type Of Material | Biological samples |
| Provided To Others? | No |
| Impact | No notable impacts as yet. Translational work utilising the samples is being planned. Other research groups will be able to gain access to the samples through a controlled-access process. |
| Title | OE05 sample collection |
| Description | Collection of blood and tumour samples from OE05 trial. |
| Type Of Material | Biological samples |
| Provided To Others? | No |
| Impact | Unknown |
| Title | PATCH sample collection |
| Description | In PATCH, blood and urine samples were collected at various time points during trial follow-up for consenting patients randomised up to end October 2013. Baseline blood samples for future research are also being collected in all consenting patients. All samples are stored at Charing Cross Hospital Assay Laboratory. |
| Type Of Material | Biological samples |
| Provided To Others? | No |
| Impact | These samples will be utilised in analyses to increase understanding of the underlying mechanisms for the potential benefits and adverse effects of the trial treatments, for example, for assessing changes in SHBG, oestrone/oestradiol ratio and bone biomarkers during time on treatment. |
| Title | TE23 sample collection |
| Description | Repositry of tumour and blood samples from participants in the TE23 trial. |
| Type Of Material | Biological samples |
| Year Produced | 2016 |
| Provided To Others? | Yes |
| Impact | Other research groups are able to gain access to the samples through application to the Trial Steering Committee. To date, samples have been shared with a research group at Cambridge University who will use the samples to investigate diagnostic and prognostic blood-based microRNA markers, and other short non-coding RNA profiles, in testicular germ cell tumours. |
| Title | TRICON8 Sample Collection |
| Description | Participants in the ICON8 trial were invited to consent to a translational research substudy to provide blood, plasma and tumour samples at the same time as consent to the main trial. Participants could consent at one of three levels depending on their preference and hospital site's resources. Sample coordination, storage and preliminary analysis is undertaken by Cambridge University. Researchers will be able to access samples via a formal application process. This sample collection will represent a valuable resource for future translational work in ovarian cancer and will represent one of the largest bio-repositories for this disease area. |
| Type Of Material | Biological samples |
| Provided To Others? | No |
| Impact | No notable impacts as yet. Translational work utilising the samples is being planned. Other research groups will be able to gain access to the samples through a controlled-access process. |
| Title | TRICON8B Sample Collection |
| Description | Participants in the ICON8B trial will be invited to consent to a translational research substudy to provide blood, plasma and tumour samples at the same time as consent to the main trial. Participants will be invited to consent at one of three levels depending on their preference and hospital site's resources. Sample coordination, storage and preliminary analysis is undertaken by Cambridge University. Dr James Brenton at Cambridge University has secured a CRUK grant for the funding of TRICON8B. Sample collection is planned to commence in q2 of 2016. Researchers will be able to access samples via a formal application process. This sample collection will represent a valuable resource for future translational work in ovarian cancer and will represent one of the largest bio-repositories for this disease area. |
| Type Of Material | Biological samples |
| Provided To Others? | No |
| Impact | No notable impacts as yet. Translational work utilising the samples is being planned. Other research groups will be able to gain access to the samples through a controlled-access process. |
| Title | TRISST clinical trial database |
| Description | Data collected specifically to allow monitoring and analysis of the primary research questions addressed by the TRISST trial. The database also includes data relevant not only to the primary question, but which provides a unique resource with which to address related questions. External groups may request access to the data through the independent Trial Steering Committee |
| Type Of Material | Improvements to research infrastructure |
| Provided To Others? | No |
| Impact | Trial is ongoing. The database is currently used for ongoing data collection, checking and monitoring. |
| Title | Urine sample collection in Add-Aspirin trial |
| Description | Urine samples are being collected at 3 time point from a subgroup of participants (n=500) in the Add-Aspirin trial. The primary purpose of the collection is to investigate platelet function (by measuring thromboxane B2) as a potential mechanism of action for anti-cancer effects of aspirin; but further translational projects utilising the samples may be developed, and the collection will be made available to other researchers (via a controlled access approach) in due course. |
| Type Of Material | Biological samples |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | None as yet. |
| Title | Add-Aspirin trial database |
| Description | A secure database with built in checks/validations, as well as functionality for producing reports, has been developed in-house to record all data collected in the trial. |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | Due to the size and scope of the planned trial (>10,000 participants with four different tumour types), the database is expected to provide a rich resource of information for use in future research beyond the original trial question. The data will be made available to other researchers via an application process. |
| Title | Add-Aspirin trial drug supply management system |
| Description | A drug supply management system initially developed to coordinate the drug supply in the Add-Aspirin trial (double-blind, randomised, controlled trial) with the flexibility to be adapted for other trials. |
| Type Of Material | Data handling & control |
| Provided To Others? | No |
| Impact | None |
| Title | BR14 - Health Economics Database |
| Description | As requested by CTAAC, we have collected data to permit a cost effectiveness analysis in UK patients. The EORTC did not wish to include this in all patients but the expectation is that there will be sufficient UK patients to enable a reliable analysis to be carried out, and the methodology applied to the analysis will be made available to other national collaborating groups who may wish to carry out their own analysis on a country-specific basis. |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | None to date - analysese will be carried out at the end of the study. |
| Title | Clinical database (OE05) |
| Description | Clinical database for OE05 trial (neo-adjuvant chemotherapy for oesophageal adenocarcinoma). |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | Not yet known. |
| Title | Clinical database (QUARTZ) |
| Description | Clinical database for QUARTZ (Quality of life after treatment for brain metastases). |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | Main trial paper published. Data available for internal and external use. |
| Title | ICON6 tumour specimen collection & associated clinical data |
| Description | Specimens from this completed clinical trial in 2nd line ovarian cancer, along with anonymised demographic and outcome data |
| Type Of Material | Database/Collection of data |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | 1st use of this collection not yet completed |
| Title | ICON7 trial specimen collection and corresponding clinical database |
| Description | Tumour and blood specimen collection from this ovarian cancer trial, along with anonymised corresponding demographic and clinical outcome data. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2010 |
| Provided To Others? | Yes |
| Impact | Multiple publications, listed as publication outputs |
| Title | ICON8 Trial Database |
| Description | A secure database with built in checks/validations, as well as functionality for producing reports, has been developed in-house to record all data collected in the trial. |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | No impact yet. The data will be made available to other researchers via an application process. |
| Title | ICON8B Trial Database |
| Description | A secure database with built in checks/validations, as well as functionality for producing reports, has been developed in-house to record all data collected in the trial. |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | No impact yet. The data will be made available to other researchers via an application process. |
| Title | PATCH and NICOR/HES cardiovascular outcome data linkage |
| Description | Cardiovascular (CVS) safety is as an important secondary endpoint within the PATCH trial. Detailed information on CVS outcomes are thus collected and regularly reviewed, which is challenging and time consuming, as it requires frequent exchanges of SAE forms and documentation between participating centres and the trial team. A pilot study will be undertaken to compare the CVS outcome data from the trial database with information from the National Institute for Cardiovascular Outcomes Research (NICOR) and the Hospital Episode Statistics (HES) databases for the patients already enrolled in PATCH, to validate methodology and data capture. |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | No impact yet as this work is currently in development. |
| Title | PATCH trial database |
| Description | A secure database with built in checks/validations, as well as functionality for producing reports, has been developed in-house to record all data collected in the trial. |
| Type Of Material | Database/Collection of data |
| Provided To Others? | No |
| Impact | No impact yet. The data will be made available to other researchers via an application process. |
| Description | A review of RCTs in recurrent ovarian cancer |
| Organisation | University College Hospital |
| Department | University College London Hospitals Charity (UCLH) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Carried out searches for trials and reviewed the results, early stage protocol development |
| Collaborator Contribution | Reviewed results of searches and early stage protocol development |
| Impact | Protocol in development |
| Start Year | 2014 |
| Description | Add-Aspirin - Sir Dorabji Tata Trust |
| Organisation | Sir Dorabji Tata Trust |
| Country | India |
| Sector | Charity/Non Profit |
| PI Contribution | Our team is leading the international Add-Aspirin clinical trial in collaboration with a group at the Tata Memorial Centre who will lead the trial in India. |
| Collaborator Contribution | The Sir Dorabji Tata Trust has agreed to provide funding to the Tata Memorial Centre to run the Add-Aspirin trial in India. |
| Impact | Securing this funding has meant that the Add-Aspirin trial can open in India. Set-up activities are currently underway. |
| Start Year | 2015 |
| Description | Add-Aspirin - Tata Memorial Hospital |
| Organisation | Tata Memorial Hospital |
| Country | India |
| Sector | Hospitals |
| PI Contribution | Leading the Add-Aspirin trial; management of the trial in the UK; oversight and mentoring of the research group at the Tata Memorial Hospital who will manage Indian participation in the trial. |
| Collaborator Contribution | Management and oversight of the Add-Aspirin trial in India. |
| Impact | In terms of the Add-Aspirin trial, the collaboration will speed up delivery of the research and enable demonstration of the health intervention in a range of settings, increasing the potential global impact of the results. Additionally, the work is facilitating development of a cancer research network in India and will pave the way for future collaborative projects. |
| Start Year | 2013 |
| Description | Add-Aspirin - Tayside tissue Bank |
| Organisation | University of Dundee |
| Department | Tayside Biorepository |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are leading and co-ordinating the Add-Aspirin clinical trial and the associated collection of biological samples from trial participants. |
| Collaborator Contribution | Tayside Tissue Bank will host the Add-Aspirin sample collection in the UK (jointly with Wales Cancer Bank) - receiving, processing and storing samples from participating trial sites. |
| Impact | The trial sample collection was initiated at the time that the trial opened to recruitment (October 2015) - collection of samples is currently ongoing. Translational work utilising the samples is being planned. |
| Start Year | 2015 |
| Description | Add-Aspirin - Wales Cancer Bank |
| Organisation | Wales Cancer Bank |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | We are leading and co-ordinating the Add-Aspirin clinical trial and the associated collection of biological samples from trial participants. |
| Collaborator Contribution | Wales Cancer Bank will host the Add-Aspirin sample collection in the UK (jointly with Tayside Tissue Bank) - receiving, processing and storing biological samples from participating trial sites. |
| Impact | The sample collection was initiated at the time that the trial opened to recruitment (October 2015) and collection of samples is currently ongoing. Translational work utilising the collection is being planned. |
| Start Year | 2015 |
| Description | Add-Aspirin PHE routine data work |
| Organisation | Public Health England |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Use of data from the Add-Aspirin clinical trial, for methodological work to assess the quality and completeness of routinely collected healthcare data, when compared with data collected within a clinical trial. |
| Collaborator Contribution | Provision of routinely collected healthcare data from a number of linked databases. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | Add-Aspirin collaboration with Cancer Trials Ireland |
| Organisation | Cancer Trials Ireland |
| Country | Ireland |
| Sector | Charity/Non Profit |
| PI Contribution | Chief Investigator and trials unit team responsible for running the Add-Aspirin clinical trial. |
| Collaborator Contribution | Delegated responsibilities for set-up and coordination of approximately 13 Irish centres that will recruit to the Add-Aspirin trial. |
| Impact | Participation of 13 Irish centres in the Add-Aspirin trial |
| Start Year | 2018 |
| Description | Add-Aspirin trial - Alcura Ltd |
| Organisation | Alcura |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Following an EU tender, a contract has been agreed with Alcura Ltd to package, label and distribute the run-in and blinded Add-Aspirin trial medication to all centres in the UK and India. Contract negotiations are now close to completion. The trial team have developed an in-house drug supply system which will be accessed to manage packaging and distribution by Alcura Ltd. |
| Collaborator Contribution | Alcura Ltd will package, label and distribute the run-in and blinded Add-Aspirin trial medication to all centres in the UK and India. |
| Impact | No outputs yet. The trial is currently in set-up. |
| Start Year | 2014 |
| Description | Add-Aspirin trial - Bayer Pharmaceuticals PLC |
| Organisation | Bayer |
| Department | Bayer HealthCare |
| Country | Germany |
| Sector | Private |
| PI Contribution | We approached Bayer to supply the drugs for the Add-Aspirin trial. |
| Collaborator Contribution | Bayer Pharmaceuticals are supplying the Add-Aspirin trial medication (100mg aspirin tablets, 300mg aspirin tablets and matched placebos) free of charge. |
| Impact | Contract signed, no output to date. The trial is currently in set-up. |
| Start Year | 2014 |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | British Columbia Cancer Agency (BCCA) |
| Department | Fraser Valley Cancer Centre |
| Country | Canada |
| Sector | Public |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | Circolo Hospital and Macchi Foundation |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | EORTC |
| Country | Belgium |
| Sector | Charity/Non Profit |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | Essen University Hospital |
| Country | Germany |
| Sector | Hospitals |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | Freeman Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | Herlev Hospital |
| Country | Denmark |
| Sector | Hospitals |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | Hospital La Luz |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | N.N. Alexandrov National Cancer Centre of Belarus |
| Country | Belarus |
| Sector | Private |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | Northern Centre For Cancer Care, Newcastle-upon-Tyne |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | Queen Elizabeth Hospital Birmingham |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | Regina Elena National Cancer Institute |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | Regional Hospital San Camillo-Forlanini |
| Country | Italy |
| Sector | Hospitals |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | Royal Marsden Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | Sapienza University of Rome |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | The Christie Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | USC Norris Cancer Hospital |
| Country | United States |
| Sector | Hospitals |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | University of Chicago |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | Uppsala University Hospital |
| Country | Sweden |
| Sector | Hospitals |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | Adjuvant chemotherapy for locally advanced bladder cancer; Update of a systematic review and IPD meta-analysis |
| Organisation | Virgen del Rocio University Hospital |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | For the original IPD meta-analysis (PMID: 15939530) protocol development; searching for trials; negotiating and managing collaborations; collecting, managing and analysing data, presenting results at conferences and preparing the final manuscript and for update protocol development; searching for trials; negotiating and managing collaborations; receiving and checking data, the project is ongoing. |
| Collaborator Contribution | Collaboration in original IPD meta-analysis or protocol development and provision of data for this update |
| Impact | 1 paper (Pre-2006), 1 Cochrane Review (PMID: 16625650) |
| Description | AstraZeneca start-up funding toward RAMPART international renal cancer adjuvant trial |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | An international consortium of key investigators in this field and a novel trial design |
| Collaborator Contribution | Provision of start-up funds and drug information in support of the planned trial (which will itself have further funding) |
| Impact | Development of trial underway and in discussion with regulatory authorities |
| Start Year | 2016 |
| Description | BR13 Collaborations |
| Organisation | European Organisation for Research and Treatment of Cancer (EORTC) |
| Country | Belgium |
| Sector | Charity/Non Profit |
| PI Contribution | The MRC Clinical Trials Unit at UCL coordinates the UK involvement in this Intergroup collaborative trial, with responsibilty for gaining and maintaining National Ethics and Regulatory approvals, and UK site approvals and initiation. Data chases and queries are relayed to and from participating UK sites via the CTU, who will intervene as required if a site is identified as performing poorly. As a result a much larger number of UK sites were able to participate (including those where the PI is not a member of the participating EORTC groups). Dr Jeremy Rees acts as the UK Chief Investigator. |
| Collaborator Contribution | The EORTC is the lead organisation and Sponsor for this trial, and oversees all participating international groups, delegating some responsibilities for the trial in the UK to the MRC CTU. The EORTC is responsible in particular for developing and maintaining the clinical trial database, and will be responsible for the trial analysis. The NCRI brain tumour CSG members supported and promoted the trial; the (former) NCRN provided the infrastructure to allow all the UK collaborating sites to take part in the trial. |
| Impact | The collaboration enabled the clinical trial to be completed, a database of the clinical data and accompanying sample collection to be developed and maintained, and initial results to be disseminated. |
| Start Year | 2006 |
| Description | BR13 Collaborations |
| Organisation | National Cancer Research Institute (NCRI) |
| Department | NCRI Brain Tumour CSG |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The MRC Clinical Trials Unit at UCL coordinates the UK involvement in this Intergroup collaborative trial, with responsibilty for gaining and maintaining National Ethics and Regulatory approvals, and UK site approvals and initiation. Data chases and queries are relayed to and from participating UK sites via the CTU, who will intervene as required if a site is identified as performing poorly. As a result a much larger number of UK sites were able to participate (including those where the PI is not a member of the participating EORTC groups). Dr Jeremy Rees acts as the UK Chief Investigator. |
| Collaborator Contribution | The EORTC is the lead organisation and Sponsor for this trial, and oversees all participating international groups, delegating some responsibilities for the trial in the UK to the MRC CTU. The EORTC is responsible in particular for developing and maintaining the clinical trial database, and will be responsible for the trial analysis. The NCRI brain tumour CSG members supported and promoted the trial; the (former) NCRN provided the infrastructure to allow all the UK collaborating sites to take part in the trial. |
| Impact | The collaboration enabled the clinical trial to be completed, a database of the clinical data and accompanying sample collection to be developed and maintained, and initial results to be disseminated. |
| Start Year | 2006 |
| Description | BR13 Collaborations |
| Organisation | National Cancer Research Institute (NCRI) |
| Department | National Cancer Research Network (NCRN) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | The MRC Clinical Trials Unit at UCL coordinates the UK involvement in this Intergroup collaborative trial, with responsibilty for gaining and maintaining National Ethics and Regulatory approvals, and UK site approvals and initiation. Data chases and queries are relayed to and from participating UK sites via the CTU, who will intervene as required if a site is identified as performing poorly. As a result a much larger number of UK sites were able to participate (including those where the PI is not a member of the participating EORTC groups). Dr Jeremy Rees acts as the UK Chief Investigator. |
| Collaborator Contribution | The EORTC is the lead organisation and Sponsor for this trial, and oversees all participating international groups, delegating some responsibilities for the trial in the UK to the MRC CTU. The EORTC is responsible in particular for developing and maintaining the clinical trial database, and will be responsible for the trial analysis. The NCRI brain tumour CSG members supported and promoted the trial; the (former) NCRN provided the infrastructure to allow all the UK collaborating sites to take part in the trial. |
| Impact | The collaboration enabled the clinical trial to be completed, a database of the clinical data and accompanying sample collection to be developed and maintained, and initial results to be disseminated. |
| Start Year | 2006 |
| Description | Barts Chemotherapy Response Score Collaboration |
| Organisation | St Bartholomew's Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Organisational input, provision of samples (omental slides) and future corresponding data |
| Collaborator Contribution | Validation of CRS system and funding of this project. |
| Impact | No outputs at present |
| Start Year | 2015 |
| Description | Canadian (CCTG) collaboration on FOCUS4 |
| Organisation | Canadian Cancer Trials Group |
| Country | Canada |
| Sector | Hospitals |
| PI Contribution | Provision of a platform for biomarker stratification and an open trial that becomes the first Canada-wide stratified medicine cancer trial |
| Collaborator Contribution | It was hoped that Canadian recruiting to FOCUS4 could begin in 2017 but they have run into funding difficulties and this arrangement is currently up in the air. |
| Impact | No outputs as yet as ultimately Canadian funding for this collaboration was not obtained |
| Start Year | 2016 |
| Description | Collaboration on health economics analysis in TRISST trial |
| Organisation | University of York |
| Department | Centre for Health Economics (CHE) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Design, conduct and management of the TRISST clinical trial |
| Collaborator Contribution | Performing health economics analyses for the TRISST clinical trial, alongside the primary (efficacy) analyses |
| Impact | No outputs to date. This is a multi-disciplinary collaboration between the TRISST Trial Management Group - which includes clinicians, statisticians and trialists - and colleagues at York University with expertise in health economics. |
| Start Year | 2008 |
| Description | Collaboration with AstraZeneca on cedaranib following ICON6 trial outcome |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Sponsored and ran the ICON6 trial after AZ abandoned development of this compound. Worked closely with them to produce licensing application. Established strong working relationship which helped with some of our other projects. |
| Collaborator Contribution | Drug supply only until positive outcome of the study was reported. Subsequently, close colloaboration on preparation of regulatory package. |
| Impact | Full study report and published manuscripts |
| Start Year | 2007 |
| Description | EORTC - BR14 |
| Organisation | European Organisation for Research and Treatment of Cancer (EORTC) |
| Country | Belgium |
| Sector | Charity/Non Profit |
| PI Contribution | The MRC CTU at UCL contributed to statistical design of the study during initial design dicussions and oversees and facilitate UK participant through an intergroup agreement with the EORTC. We are responsbile for ethics and regulatory approval and reporting and UK site management. As a result of our involvement any approved UK site may participate in the trial without this only EORTC member sites would be able to take part substanitally limiting accrual. |
| Collaborator Contribution | Intergroup collaboration has enabled this trial, which is in a relatively rare type of brain tumour to take place. The overall trial co-ordination and sponsorship is taken by the EORTC. |
| Impact | The trial completed recruitment in 2015. |
| Start Year | 2008 |
| Description | EURAMOS |
| Organisation | Cooperative Osteosarcoma Study Group |
| Country | European Union (EU) |
| Sector | Academic/University |
| PI Contribution | Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining. |
| Collaborator Contribution | Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough. |
| Impact | No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting). |
| Description | EURAMOS |
| Organisation | European and American Osteosarcoma Study Group (EURAMOS) |
| Department | European Osteosarcoma Group (EOI) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining. |
| Collaborator Contribution | Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough. |
| Impact | No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting). |
| Description | EURAMOS |
| Organisation | Merck |
| Department | Schering Plough |
| Country | United States |
| Sector | Private |
| PI Contribution | Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining. |
| Collaborator Contribution | Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough. |
| Impact | No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting). |
| Description | EURAMOS |
| Organisation | Merck |
| Country | Germany |
| Sector | Private |
| PI Contribution | Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining. |
| Collaborator Contribution | Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough. |
| Impact | No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting). |
| Description | EURAMOS |
| Organisation | National Cancer Institute (NCI) |
| Department | Children's Oncology Group (COG) |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining. |
| Collaborator Contribution | Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough. |
| Impact | No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting). |
| Description | EURAMOS |
| Organisation | National Cancer Research Institute (NCRI) |
| Department | NCRI Bone Cancer CSG |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining. |
| Collaborator Contribution | Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough. |
| Impact | No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting). |
| Description | EURAMOS |
| Organisation | National Cancer Research Institute (NCRI) |
| Department | National Cancer Research Network (NCRN) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining. |
| Collaborator Contribution | Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough. |
| Impact | No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting). |
| Description | EURAMOS |
| Organisation | Scandinavian Sarcoma Group (SSG) |
| Country | Sweden |
| Sector | Charity/Non Profit |
| PI Contribution | Design, central coordination and analysis of trial data. Discussion, prioritisation and design of further clinical trials from this. New participants to the group are currently joining. |
| Collaborator Contribution | Design and conduct of clinical trials This organisation involves a number of countries. Many of these countries provide money to a central pot. This pot provides money to support the running of the trial, including to MRC CTU. Design and conduct of clinical trials. This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms. EURAMOS-1 is run in collaboration with the NCRI bone cancer Clinical Studies Group which, as a group, encourages national participation in trials. Each of the collaborating groups named above includes representatives from a number of countries. In each country, a university is acting as the delegate for many of the MRC's responsibilities as Sponsor. These are not named in detail here but are listed in the EURAMOS-1 European Framework agreement which they have co-signed. Continued provision of free drug (Peg-intron)interferon by Merck for clinical trial use and distribution to trial sites, following their take-over of Schering Plough. |
| Impact | No primary publications yet. Methods and collaboration paper now presented and added as a publication (PMID: 20213400). Invitations to present on high-profile collaboration at international conferences and to EU-level discussions of lessons learned in being the first academic trial to run internationally after the implementation of the EU Clinical Trials Directive (EC\2001\20). 1st results from the good responders randomisation were presented at American Society of Clinical Oncology Annual Meeting 2013 in the oral sarcoma session (and was the only oral presentation on bone sarcoma at the meeting). |
| Description | Gynecologic Cancer InterGroup (GCIG) |
| Organisation | Gynecologic Cancer InterGroup (GCIG) |
| Country | Canada |
| Sector | Charity/Non Profit |
| PI Contribution | The Gynecologic Cancer Intergroup is an international collaboration of clinical trialists, whose aims are to promote and conduct high quality clinical trials in order to improve outcomes for women with gynecologic cancer. The MRC CTU contributes strongly to this collaboration with the majority of our trials being badged as GCIG trials. The contributions of this group include providing a forum for discussion on clinical trial development and prioritisation of research questions, harmonisation of clinical trial operations, participation in international clinical trial recruitment and meta-analyses. |
| Collaborator Contribution | Collaboration in trials and harmonisation of processes and procedures |
| Impact | Completion of recruitment of ICON7 trial from over 300 clinical sites in 11 countries. Publication of results from ICON5 trial, a GCIG collaboration with UK, US, Italy, Australia and New Zealand (pub med 19224846). Recruitment to ICON6 trial (currently open in UK and Canada). Recruitment to ICON8 trial (currently open in Korea and UK). International collaboration on clinical trials as outlined in publication 19720905 |
| Description | ICON8 trial (NCT10356837) |
| Organisation | Australia and New Zealand Gynaecological Oncology Group |
| Country | Australia |
| Sector | Charity/Non Profit |
| PI Contribution | Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer |
| Collaborator Contribution | CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally. |
| Impact | Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant. |
| Start Year | 2010 |
| Description | ICON8 trial (NCT10356837) |
| Organisation | Cancer Research UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer |
| Collaborator Contribution | CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally. |
| Impact | Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant. |
| Start Year | 2010 |
| Description | ICON8 trial (NCT10356837) |
| Organisation | European Society of Gynaecological Oncology (ESGO) |
| Department | European Network of Gynaecological Oncology Trials Groups (ENGOT) |
| Country | Czech Republic |
| Sector | Charity/Non Profit |
| PI Contribution | Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer |
| Collaborator Contribution | CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally. |
| Impact | Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant. |
| Start Year | 2010 |
| Description | ICON8 trial (NCT10356837) |
| Organisation | Gynecologic Cancer InterGroup (GCIG) |
| Country | Canada |
| Sector | Charity/Non Profit |
| PI Contribution | Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer |
| Collaborator Contribution | CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally. |
| Impact | Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant. |
| Start Year | 2010 |
| Description | ICON8 trial (NCT10356837) |
| Organisation | Irish Clinical Oncology Research Group (ICORG) |
| Country | Ireland |
| Sector | Charity/Non Profit |
| PI Contribution | Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer |
| Collaborator Contribution | CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally. |
| Impact | Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant. |
| Start Year | 2010 |
| Description | ICON8 trial (NCT10356837) |
| Organisation | Korean Gynaecological Oncology Group |
| Country | Korea, Republic of |
| Sector | Charity/Non Profit |
| PI Contribution | Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer |
| Collaborator Contribution | CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally. |
| Impact | Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant. |
| Start Year | 2010 |
| Description | ICON8 trial (NCT10356837) |
| Organisation | National Cancer Research Institute (NCRI) |
| Department | NCRI Gynaecological Oncology CSG |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer |
| Collaborator Contribution | CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally. |
| Impact | Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant. |
| Start Year | 2010 |
| Description | ICON8 trial (NCT10356837) |
| Organisation | Research Group on Ovarian Cancer and Gynecologic Tumors of Mexico (GICOM) |
| Country | Mexico |
| Sector | Charity/Non Profit |
| PI Contribution | Trial development and lead group for an important trial of dose fractionated chemotherapy for women with newly diagnosed ovarian cancer |
| Collaborator Contribution | CR UK Peer reviewed and approved ICON8 as well as funding it. The trial is run through the NCRI infrastructure in the UK. The other groups are collaborating partners and GCIG members, activating the trial to run internationally. |
| Impact | Trial opened in the UK in June 2011 and is actively recruiting patients. Trial opened internationally in Korea in October 2012, in Mexico and Ireland in 2013 and in Australia and New Zealand in 2014. An ancillary sample collection study (TRICON8) has been established in collaboration with the University of Cambridge Cancer Research Institute and funded via a CRUK CTAAC grant. |
| Start Year | 2010 |
| Description | PATCH HES/PHE methodology work. |
| Organisation | Public Health England |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Methodological work within PATCH, assessing the quality and completeness of routinely collected healthcare data, compared to data colected within the trial. |
| Collaborator Contribution | Provision of routinely collected healthcare data from a number of linked databases. |
| Impact | None as yet |
| Start Year | 2019 |
| Description | PATCH bone biomarker sub-study |
| Organisation | Imperial College London |
| Department | Imperial College Trust |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | We are working with Dr Richie Abel, who is a lecturer in Musculoskeletal Sciences, on a proposal to compare changes in bone biomarkers between treatment arms (oestrogen patches vs LHRHa) within the PATCH trial. |
| Collaborator Contribution | Dr Richie Abel is leading on the proposal and will coordinate the analysis of the stored serum samples. |
| Impact | The proposal is currently in development. |
| Start Year | 2015 |
| Description | PATCH trial Progynova sub-study - Bayer Plc |
| Organisation | Bayer |
| Department | Bayer HealthCare |
| Country | Germany |
| Sector | Private |
| PI Contribution | We approached Bayer Plc to supply the Progynova oestrogen patches for a sub-study within the main PATCH trial. |
| Collaborator Contribution | Bayer Plc will provide the Progynova patches at a 37% discount price, and will ensure the supply of the patches for the sub-study. |
| Impact | Ninety patients were recruited to the sub-study from 9 sites. In the final analysis, the 12-weeks castration rate (testosterone =1.7nmol/L) in the Progynova arm was 100%, confirming these patches can effectively achieve castrate levels of testosterone within this setting at a similar dose regimen to that used for FemSeven patches. |
| Start Year | 2015 |
| Description | RADICALS (MRC PR10) trial (NCT00541047) |
| Organisation | Canadian Cancer Society |
| Department | Canadian Cancer Society Research Institute |
| Country | Canada |
| Sector | Academic/University |
| PI Contribution | Design, central coordination and analysis of the RADICALS trial |
| Collaborator Contribution | Coordination of RADICALS trial in Canada This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial |
| Impact | Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC). |
| Start Year | 2006 |
| Description | RADICALS (MRC PR10) trial (NCT00541047) |
| Organisation | Cancer Research UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Design, central coordination and analysis of the RADICALS trial |
| Collaborator Contribution | Coordination of RADICALS trial in Canada This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial |
| Impact | Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC). |
| Start Year | 2006 |
| Description | RADICALS (MRC PR10) trial (NCT00541047) |
| Organisation | National Cancer Research Institute (NCRI) |
| Department | NCRI Prostate Cancer CSG |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Design, central coordination and analysis of the RADICALS trial |
| Collaborator Contribution | Coordination of RADICALS trial in Canada This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial |
| Impact | Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC). |
| Start Year | 2006 |
| Description | RADICALS (MRC PR10) trial (NCT00541047) |
| Organisation | National Cancer Research Institute (NCRI) |
| Department | National Cancer Research Network (NCRN) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Design, central coordination and analysis of the RADICALS trial |
| Collaborator Contribution | Coordination of RADICALS trial in Canada This trial is a collaboration with the National Cancer Research Network (a component of NIHR and funded by the English Dept of Health) and the corresponding networks in the other UK nations. It specifically includes all the staff at each of the clinical sites that have participated in this clinical trial. Each site identified patients potentially suitable for the trial, sought informed consent, treated and followed-up patients within the trial and provided data through completion and return of case record forms.The trial is run in collaboration with the NCRI prostate cancer CSG which as a group encourages national participation in the trial |
| Impact | Clinical trial. Multi-disciplinary: oncology, urology, statistics, operations. Results are awaited; accrual is ongoing. Outputs only relate to trial promotion and justification. All papers are listed in the previous section. Sites in Denmark and Ireland have been activated. Sites in Spain and Sweden are considering the trial. A planned collaboration with the USA (through RTOG) failed at the final hurdle. A meta-analysis of relevant trials is being planned prospectively call ARTISTIC - see MC_U122861323. This involves collaboration with France (Unicancer), Australasia (TROG), USA (RTOG) and Europe (EORTC). |
| Start Year | 2006 |
| Description | RADICALS and Canada |
| Organisation | National Cancer Institute of Canada Clinical Trials Group |
| Country | Canada |
| Sector | Public |
| PI Contribution | RADICALS trial is led from MRC CTU at UCL |
| Collaborator Contribution | Canadian sites have engaged in recruiting, treating and following-up patients. This has been organised by the Canadian Cancer Trials Group. |
| Impact | Results from the trial will follow on 2018 to 2020 |
| Start Year | 2007 |
| Description | RADICALS and Denmark |
| Organisation | Danish Cancer Society |
| Country | Denmark |
| Sector | Charity/Non Profit |
| PI Contribution | RADICALS trial is led from MRC CTU at UCL |
| Collaborator Contribution | Danish sites in Copenhagen, Aarhus and elsewhere have collaborated in recruiting, treatment and following-up patients |
| Impact | Results to follow 2018-2020 |
| Start Year | 2010 |
| Description | Second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis |
| Organisation | Royal Sussex County Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | Searched for and categorised trials, analysed results, interpreted results and wrote manuscript |
| Collaborator Contribution | Contributed to project design and manuscript |
| Impact | 1 publication (PMID: 30482913) |
| Start Year | 2015 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | Addenbrooke's Hospital |
| Department | Department of Oncology |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | Antwerp University Hospital |
| Country | Belgium |
| Sector | Hospitals |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | Germans Trias i Pujol University Hospital |
| Country | Spain |
| Sector | Hospitals |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | Guangdong General Hospital |
| Country | China |
| Sector | Hospitals |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | Gustave-Roussy Institute |
| Country | France |
| Sector | Academic/University |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | Helsinki University Central Hospital |
| Country | Finland |
| Sector | Hospitals |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | Pitié-Salpêtrière Hospital |
| Country | France |
| Sector | Hospitals |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | University College London Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | University Hospital of Besancon |
| Country | France |
| Sector | Hospitals |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | University Hospitals of Leicester NHS Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | University Medical Center Gronigen |
| Country | Netherlands |
| Sector | Hospitals |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | University of Colorado |
| Department | Cancer Centre |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | University of Texas |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | University of Turin |
| Country | Italy |
| Sector | Academic/University |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | University of York |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | Vanderbilt University |
| Country | United States |
| Sector | Academic/University |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | Staging accuracy in non-small cell lung cancer |
| Organisation | Yokohama City University Medical Centre |
| Country | Japan |
| Sector | Hospitals |
| PI Contribution | The research team conducted the original systematic review and meta-analysis. The research team analysed the data for the secondary staging accuracy project and drafted the manuscript |
| Collaborator Contribution | The partners supplied the original individual participant data and commented on the manuscript for the secondary staging accuracy project |
| Impact | 1 presentation of original project at World Lung Cancer Conference 2011 and 1 paper in Lancet (PMID: 24576776). Secondary analysis for staging accuracy, 1 manuscript (PMID: 30391190) |
| Start Year | 2006 |
| Description | TE23 data and sample sharing - University of Cambridge |
| Organisation | University of Cambridge |
| Department | Department of Pathology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of biological samples and data collected within the TE23 clinical trial in testicular cancer |
| Collaborator Contribution | Undertaking a project utilising the data and samples from the TE23 clinical trial |
| Impact | None |
| Start Year | 2016 |
| Description | TRICON8B |
| Organisation | Cancer Research UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | We will facilitate entry of patients consenting to the ICON8B trial into the associated translational studies and keep records of samples collected via the Translational Research CRF. |
| Collaborator Contribution | Collection, handling, storage and preliminary analysis of blood and tissue samples collected from consenting ICON8B patients. |
| Impact | Establishment of a tissue bank linked to the ICON8 trial |
| Start Year | 2016 |
| Description | TRISST trial |
| Organisation | National Cancer Research Institute (NCRI) |
| Department | NCRI Testis Tumour CSG |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Trial design, coordination and analysis |
| Collaborator Contribution | This trial is a collaboration with the NCRN which provides infrastructure support for conducting studies across the UK. The participating sites are responsible for the identification, consent and entry of patients into the trial, administration of trial procedures and provision of patient data. The NCRI Testis Cancer CSG has helped support the set up of the trial and helps promote collaboration and participation. |
| Impact | Ongoing. This is a multi-disciplinary collaboration including clinicians and research nurses at participating sites, as well as statisticians and trial/data management staff at the trials unit. |
| Start Year | 2008 |
| Description | TRISST trial |
| Organisation | National Cancer Research Institute (NCRI) |
| Department | National Cancer Research Network (NCRN) |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Trial design, coordination and analysis |
| Collaborator Contribution | This trial is a collaboration with the NCRN which provides infrastructure support for conducting studies across the UK. The participating sites are responsible for the identification, consent and entry of patients into the trial, administration of trial procedures and provision of patient data. The NCRI Testis Cancer CSG has helped support the set up of the trial and helps promote collaboration and participation. |
| Impact | Ongoing. This is a multi-disciplinary collaboration including clinicians and research nurses at participating sites, as well as statisticians and trial/data management staff at the trials unit. |
| Start Year | 2008 |
| Description | TransMAGIC - CLOVIS |
| Organisation | Clovis Oncology, inc |
| Country | United States |
| Sector | Private |
| PI Contribution | Supply of tumour samples and clinical data from MAGIC. At a later date will be involved in reviewing the output of the work. |
| Collaborator Contribution | Will be analysing the tumour samples, and performing statistical analysis on the data. |
| Impact | Collaboration only recently started, so no output yet. |
| Start Year | 2015 |
| Description | UCL - Astra Zeneca: RAMPART Trial - Main Collaboration Agreement |
| Organisation | AstraZeneca |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | MRC CTU at UCL has led on the design of this trial, is leading on all aspects of trial conduct and will lead on all aspects of trial analysis, reporting and the dissemination of results. |
| Collaborator Contribution | Astra Zeneca have agreed to provide USD$22,000,000 to support the cost of the trial. They are also providing free trial drugs to sites (including cost of distribution). |
| Impact | No outputs to date. |
| Start Year | 2018 |
| Description | UCL - Kidney Cancer UK - RAMPART Trial |
| Organisation | Kidney Research UK |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | MRC CTU at UCL has led on the design of the RAMPART trial, is leading on all aspects of trial conduct and will lead on all aspects of trial analysis, reporting and the dissemination of results. |
| Collaborator Contribution | Kidney Cancer UK peer-reviewed and approved the RAMPART trial, consequently the trial was adopted onto the NCRI trials portfolio. Kidney Cancer UK have agreed to provide funding to support patient-centred activities. |
| Impact | No outcomes to date |
| Start Year | 2018 |
| Description | Vitamin D as a cancer therapy |
| Organisation | Brighton and Sussex University Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Assisted in searching for trials, categorised trials, tabulated results, contributed to manuscript and interpretation of results |
| Collaborator Contribution | Collated information and wrote the majority of the manuscript |
| Impact | One manuscript published (PMID: 26520788) |
| Start Year | 2014 |
| Title | Add-Aspirin clinical trial |
| Description | The Add-Aspirin trial opened to recruitment in the UK in 2015 - it will investigate whether regular aspirin following treatment for an early stage common cancer can prevent recurrence and improve survival. Recruitment is currently ongoing. Funding for the trial is being provided by Cancer Research UK and the NIHR Heath Technology Assessment Programme. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2015 |
| Development Status | Under active development/distribution |
| Impact | None as yet. |
| URL | http://www.addaspirintrial.org/ |
| Title | ICON8B |
| Description | A phase III randomised trial investigating the combination of dose-fractionated chemotherapy and bevacizumab compared to either strategy alone for the first-line treatment of women with newly diagnosed high-risk stage III-IV epithelial ovarian, fallopian tube or primary peritoneal cancer. Submitted as an amendment to the ICON8 protocol. First site opened to recruitment in July 2015. Recruitment on going as of February 2017 (expected to complete recruitment in July 2019). The trial is funded by CRUK and the MRC. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2015 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | Pending |
| URL | http://www.isrctn.com/ISRCTN10356387?q=&filters=recruitmentCountry:Mexico&sort=relevance&offset=73&t... |
| Title | PATCH trial |
| Description | PATCH is a randomised, non-inferiority, phase III trial comparing the clinical efficacy and side effect profile of transdermal oestradiol (tE2) with Luteinising Hormone Releasing Hormone agonists (LHRHa) in the treatment of locally advanced and metastatic prostate cancer. Transdermal oestradiol avoids first-pass hepatic metabolism and therefore is not expected to be associated with the cardiovascular (CVS) toxicity previously seen with oral oestrogen. It also avoids some of the serious side-effects associated with LHRHa. The primary outcome measures will be overall survival and progression-free survival. The secondary outcome measures include prostate cancer specific survival, hormone levels, CVS and other toxicity, and quality of life. Data from the trial so far have shown promising evidence of the safety and efficacy of tE2. Results from the first stage of the trial have been published (n= 254), showing tE2 produced castrate levels of testosterone similar to LHRHa, with no evidence of excess CVS toxicity. During the second stage, a pre-planned interim analysis (n=638) reviewed by the Independent Data Monitoring Committee in June 2013 led to the trial being extended for a phase III evaluation of the efficacy of tE2. Since June 2017, a new tE2 comparison has been added to the STAMPEDE trial platform to compare tE2 against standard methods for androgen deprivation therapy, to complement the PATCH trial. The clinical efficacy of tE2 will henceforth be evaluated using relevant data from the PATCH and STAMPEDE trials combined, using a meta-analysis approach. This efficient approach enables faster recruitment to the comparison and activation of the comparison at additional UK sites. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2013 |
| Development Status | Under active development/distribution |
| Impact | Results from a bone health sub-study embedded within PATCH have shown tE2 protects against the bone mineral density loss seen with LHRHa. In addition, patients on tE2 appear to develop more favourable metabolic profiles and have a number of improved short-term quality of life outcomes compared to those on LHRHa therapy. However, the clinical efficacy of tE2 needs confirming within a phase III trial setting before they can be considered as part of standard care in prostate cancer. |
| Title | PATCH trial Progynova sub-study |
| Description | Until recently, the patch brand solely used in the PATCH trial was FemSeven. However, it is known that there are differences in the pharmacokinetic properties between different brands of patches. Therefore, a small sub-study embedded within the main trial is currently underway to evaluate an alternative brand of patches, namely the Progynova TS. This is to confirm the appropriate dose regimen for the Progynova for achieving castrate levels of testosterone within this setting. The primary outcome measure is castration rate at 12 weeks. Approximately 70 patients are to be randomised in allocation ratio 2:1 of patches:LHRHa. The sub-study is expected to be completed around end 2016. |
| Type | Therapeutic Intervention - Drug |
| Current Stage Of Development | Early clinical assessment |
| Year Development Stage Completed | 2015 |
| Development Status | Under active development/distribution |
| Impact | Results from the sub-study will be important for ensuring the long-term supply of the patches for the main PATCH trial, and broaden the re-purposing element of the study. |
| Title | PROMIS MRI methods and description of needed validation for widespread use |
| Description | The MRC PROMIS trial established clearly the potential benefit, and the cost-effectiveness, of an MRI imaging step between identification of patients as possibly needing a prostate biopsy and the trans-rectal biopsy procedure itself. What remains to be done to ascertain whether high quality imaging and consistent radiographic interpretation in high volume can be implemented widely across the NHS. |
| Type | Diagnostic Tool - Imaging |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2016 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | - |
| Title | TRISST (TE24) |
| Description | Surveillance is an increasingly widely used management option for patients with stage I testicular seminoma, but requires regular radiological surveillance in order to detect recurrences early. CT scans are most widely used, but frequency varies considerably, and radiation associated with their use is a serious concern in this young, good prognosis population. The TRISST trial is factorial non-inferiority trial looking at 2 ways of potentially reducing radiation associated with surveillance scanning: a reduced scan frequency and/or replacement of CT scans with MRI scans. The trial is currently open to recruitment, due to complete in 2014, and is funded by CR UK |
| Type | Diagnostic Tool - Imaging |
| Current Stage Of Development | Late clinical evaluation |
| Year Development Stage Completed | 2008 |
| Development Status | Under active development/distribution |
| Clinical Trial? | Yes |
| Impact | None as yet - this is the only randomised trial addressing these questions. |
| URL | http://www.isrctn.com/ISRCTN65987321 |
| Title | Add-Aspirin Drug Supply Management System |
| Description | A drug supply management system tailored to the trial requirements has been developed in-house to provide a secure system for coordinating all aspects of the drug supply process in the study. The drug packaging and distribution team, as well as research staff and pharmacists at participating sites will have web-based access to the system, and it will allow close oversight of the whole process by the Trials Unit team. Input from all of the relevant parties has been sought in developing the system and it has been designed in such a way that it can subsequently be adapted for use in future trials conducted at the unit. |
| Type Of Technology | Software |
| Year Produced | 2014 |
| Impact | This in-house system may replace the need to out-source the management of drug supply processes, and so will have cost-saving implications both within Add-Aspirin and for future trials. |
| Description | ACED Online Seminar Series |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | ACED (International Alliance for Cancer Early Detection) Meet & Greet: Epidemiological Approaches for Early Detection - Dr Gentry-Maharaj and Dr Apostolidou gave a pitch on their research interests and skills, and what they were looking for in a collaborator. Dr Sophia Apostolidou was speaker for an online seminar run by ACED Alliance - 'UKCTOCS Longitudinal Women's Cohort for early detection cancer research'. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Add-Aspirin interview for BBC World TV |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Professor Langley gave an interview for BBC World TV about the launch of the Add-Aspirin clinical trial. The launch was picked up by the news media internationally and prompted requests for further information, both from the general public and from other research groups. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Add-Aspirin interview for Today Programme |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | Professor Langley gave a radio interview for the Today Programme about the launch of the Add-Aspirin clinical trial. The launch was picked up by the news media internationally and prompted requests for further information about the trial from both the general public and other research groups. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Add-Aspirin interview in The Observer |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Interview regarding the Add-Aspirin trial included in an article in The Observer |
| Year(s) Of Engagement Activity | 2016 |
| URL | https://www.theguardian.com/science/2016/jun/12/anti-cancer-drugs-medicine-cabinet-repurposed-aspiri... |
| Description | Add-Aspirin leaflets at the NCRN Clinical Studies Group trials meetings |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Leaflets about the Add-Aspirin trial were included in delegate packs for the NCRN urological and breast Clinical Studies Group trials meetings early in 2016, and some of the trials unit team attended the meetings. Attendees at the meetings included research teams from sites that were already participating in the trial and some that were going through the set-up process or interested in participating. Thus, it provided an opportunity to engage with these researchers and further raise awareness of the trial. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Add-Aspirin methodology seminar at ICR CTSU |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited to give a trials methodology seminar at the Institute of Cancer Research clinical trials unit covering novel aspects in the design and conduct of the Add-Aspirin trial. The talk prompted some interesting discussions and is expected to lead to future sharing of knowledge and experience between the two trials units. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Add-Aspirin oral presentation at ESMO world congress on Gastrointestinal Cancer Conference 2014 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Health professionals |
| Results and Impact | Oral presentation and poster presentation entitled "Are the Benefits of Aspirin in Colorectal Cancer Limited to PIK3CA Mutated Cancers?" at an international conference. The talk promoted discussion and raised awareness of the Add-Aspirin trial. Promoted discussion |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://annonc.oxfordjournals.org/content/25/suppl_2/ii109.3.short |
| Description | Add-Aspirin poster at BAUS meeting 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster on Add-Aspirin trial prostate cohort presented at the British Association of Urological Surgeons annual meeting (June 2017) |
| Year(s) Of Engagement Activity | 2017 |
| Description | Add-Aspirin poster at the American Society of Clinical Oncology (ASCO) annual meeting |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Type Of Presentation | poster presentation |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presented at the largest oncology conference worldwide to raise awareness and promote interest in the Add-Aspirin trial: "Add-Aspirin Trial: A phase III, double blind, placebo-controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours". Trial promotion and discussion with international experts |
| Year(s) Of Engagement Activity | 2014 |
| URL | http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS1617 |
| Description | Add-Aspirin posters at BAUS meetings |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Posters on the Add-Aspirin clinical trial were displayed at the British Association of Urological Surgeons annual scientific meeting and annual meeting in June and November 2015. The posters were designed to raise awareness of the trial amongst this community who will play a key role in recruitment to the prostate cancer cohort of the trial. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Add-Aspirin presentation at Thames Valley Cancer Research Network event |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Professor Langley gave a presentation about the Add-Aspirin trial at the Thames Valley Cancer Research Network away-day. This was an opportunity to engage with research teams at sites that might participate in the trial. Subsequently, a number of sites in this network have opened to recruit to the trial. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Add-Aspirin press releases for trial launch |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Media (as a channel to the public) |
| Results and Impact | A national press release, and a number of regional releases, were published to announce the launch of the Add-Aspirin clinical trial. The release was picked up by the news media internationally and prompted a number of requests for interviews from the media and requests for further information about the trial from both the general public and other research groups. |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2015-10-22-worlds-largest-clinica... |
| Description | Add-Aspirin trial launch meeting at NCRI conference Liverpool 2014 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Health professionals |
| Results and Impact | Add-Aspirin trial launch meeting- Trial promotion and training for research nurses and doctors hoping to participate in the trial at their site. Increased requests for further information from sites interested in participating in the trial. |
| Year(s) Of Engagement Activity | 2014 |
| Description | Add-Aspirin trial training events for participating site teams |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prior to opening the Add-Aspirin clinical trial, two training events were held (in London and in Edinburgh) which were designed to provide teams from participating sites information about the trial and guidance on running it at their site. Attendees included Research Nurses, Trial Co-ordinators, Pharmacists and Clinicians. Other similar training sessions were held via WebEx, reaching staff at more than 100 sites expecting to participate in the trial. Most attendees have subsequently completed the trial set-up process and opened their site to recruit to the trial. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Add-Aspirin website |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Study participants or study members |
| Results and Impact | The Add-Aspirin clinical trial website has been designed to provide information and updates about the trial to study participants, research teams at participating trial sites, other research groups and the general public. |
| Year(s) Of Engagement Activity | 2015 |
| URL | http://www.addaspirintrial.org |
| Description | Adjuvant aspirin talk at NCI think tank meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation about current research on aspirin in the adjuvant setting given at the U.S. National Cancer Institute think tank meeting on aspirin and non-steroidal anti-inflammatory drugs in cancer prevention |
| Year(s) Of Engagement Activity | 2021 |
| Description | Aspirin and cancer - ESMO 2017 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Ruth Langley presented a talk entitled "Aspirin for prevention and adjuvant treatment of cancer" at the European Society for Medical Oncology (ESMO) annual congress in September 2017, Madrid, Spain. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Aspirin trialists collaborative group meeting (Vienna, 2015) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | This was the initial meeting of a new collaborative group of international researchers leading trials investigating the effects of aspirin in colorectal cancer. The formation of this group is expected to lead to future formal collaborations - for example, on meta-analyses of trial data. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Briefing paper on QUARTZ results |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Policymakers/politicians |
| Results and Impact | We produced a briefing paper about the QUARTZ trial results, aimed at policymakers and practitioners. |
| Year(s) Of Engagement Activity | 2016 |
| URL | http://www.ctu.mrc.ac.uk/12602/13009/quartz_briefing_paper_020916 |
| Description | EURAMOS good responders lay summary |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | Lay summary of trial results (First results of the EURAMOS-1: Information for trial participants and families) was prepared and made available via the trial website and sent to investigators to give to participants. Unknown |
| Year(s) Of Engagement Activity | 2013 |
| URL | http://www.euramos.org |
| Description | EURAMOS-1 Overview at NCRI 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation of EURAMOS-1 design, results (particularly Poor Response randomisation) and implications at UK National Cancer Research Institute 2015 conference by Jeremy Whelan (UCL, London). This was an invited talk to a session on clinical trials in rare cancers. |
| Year(s) Of Engagement Activity | 2015 |
| Description | EURAMOS-1 Poor Responders at CTOS 2014 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | The results of the Poor Response randomisation of the EURAMOS-1 were presented for the first time at the Connective Tissue Oncology Society meeting 2015 in Berlin, Germany, by Neyssa Marina (Stanford, CA, USA), one of the lead clinicians for the trial. The analysis were done and the slides prepared by MRC CTU at UCL. This will change practice despite not finding in favour of the research arm. A paper was submitted for publication late in 2015. |
| Year(s) Of Engagement Activity | 2014 |
| Description | EURAMOS-1 surgery data: oral presentation at CTOS 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Data on surgery in EURAMOS-1 trial were presented orally at the Connective Tissue Oncology Society meeting 2015 in Salt Lake City, UT, USA. The presentation was given by surgeon Rob Grimer. The analyses were led by, and slides prepared by, MRC CTU at UCL. |
| Year(s) Of Engagement Activity | 2015 |
| Description | EURAMOS-1 surgery data: oral presentation at ISOLS 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Data on surgery in EURAMOS-1 trial were presented orally at the International Society Of Limb Salvage meeting 2015 in Florida, USA. The presentation was given by surgeon Rob Grimer. The analyses were led by, and slides prepared by, MRC CTU at UCL. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Event to receive donation from Friends of CRUK on behalf of CRUK |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Supporters |
| Results and Impact | Attendance at a publicised event to accept a donation of £45,000 on behalf of Cancer Research UK from the Putney, Barnes, Sheen and Kew Group of Friends of Cancer Research UK. This donation was a result of the South West London Christmas Fair fundraising event. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Films about PROMIS results |
| Form Of Engagement Activity | A broadcast e.g. TV/radio/film/podcast (other than news/press) |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Prostate Cancer UK, in partnership with the MRC Clinical Trials Unit at UCL, has released a series of short films on how multi-parametric MRI scans can improve prostate cancer diagnosis. These films are based on the results of the PROMIS study. Two of the films are aimed at clinicians, giving a summary of the study and its results, and how mpMRI can be used a triage for TRUS biopsy. The third film is aimed at patients, exploring the PROMIS results and what they mean for prostate cancer diagnosis. |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://www.youtube.com/playlist?list=PL1E-4A23O0jxZK4hJcghd0OgDnh4Z03VH |
| Description | ICON8 ASCO 2014 Poster |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presenting an update to the ICON8 trial at ASCO 2014 |
| Year(s) Of Engagement Activity | 2014 |
| Description | ICON8 ENGOT Frankfurt 2014 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Trial update presentation |
| Year(s) Of Engagement Activity | 2014 |
| Description | ICON8 ENGOT Liverpool 2013 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Trial update presentation |
| Year(s) Of Engagement Activity | 2013 |
| Description | ICON8 ENGOT Madrid 2014 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Trial update presentation |
| Year(s) Of Engagement Activity | 2014 |
| Description | ICON8 ENGOT Nice 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Trial update presentation |
| Year(s) Of Engagement Activity | 2015 |
| Description | ICON8 ENGOT Vienna 2012 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Trial Update Presentation |
| Year(s) Of Engagement Activity | 2012 |
| Description | ICON8 ESGO Stage 1A results |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | ICON8 Stage 1A results |
| Year(s) Of Engagement Activity | 2013,2014 |
| Description | ICON8 GCIG Chicago 2014 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Trial update presentation |
| Year(s) Of Engagement Activity | 2006,2014 |
| Description | ICON8 GCIG Chicago 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Trial update presentation |
| Year(s) Of Engagement Activity | 2015 |
| Description | ICON8 GCIG London 2013 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Trial update presentation |
| Year(s) Of Engagement Activity | 2013 |
| Description | ICON8 GCIG Melbourne 2014 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Trial update presentation |
| Year(s) Of Engagement Activity | 2014 |
| Description | ICON8 GCIG Stage 1A results |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | ICON8 GCIG Stage 1A results |
| Year(s) Of Engagement Activity | 2013 |
| Description | ICON8 GCIG Tokyo 2015 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Trial update |
| Year(s) Of Engagement Activity | 2015 |
| Description | ICON8 Launch Meeting 2012 |
| Form Of Engagement Activity | A talk or presentation |